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Abstract 
6-Methoxytetrahydroisoquinoline hydrochloride was converted into four small libraries of substituted ureas, 
thioureas, sulfonamides and N-aryls, using the tetrahydroisoquinoline nitrogen as the scaffold-linking atom. 
Some of the compounds were evaluated for their ability to inhibit cell proliferation using the MCF7 (invasive 
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Introduction 
 
The estrogen receptor (ER) is a critical component for the control of cellular processes in mammalian tissue.2 
Its ligands, including the hormone estradiol 1 (Figure 1, also written as oestradiol), are important for signal 
transduction processes crucial to many aspects of cellular life and death.3 Cellular estrogenic activity is 
mediated by plasma membrane nuclear receptors which exist in two isoforms, ERα and ERβ, which further 
control a multitude of physiological responses and activities.2,4,5 The two isoforms are differentially distributed 
within the tissue domains, with ERα being dominantly expressed in the uterus and mammary glands, while 
ERβ is more generally expressed throughout the body. Of specific significance is that the natural occurrence of 
estradiol in women affected with breast cancer may either worsen the disease, or a deficiency thereof could 
effect a cascade of hormonal related ailments. The importance of the relationship between estradiol and 
breast cancer has resulted in the development of a series of drugs termed selective estrogen receptor 





Figure 1.  Structures of estradiol and THIQ motifs, including the tetrahydroisoquinolin-6-ol motif 2b important 
in this study. 
 
The tetrahydroisoquinoline (THIQ) scaffold 2a (R = H, Figure 1) has been shown to be an extremely 
valuable motif in medicinal chemistry, and as a result has found regular application in pharmaceutical 
investigations.8 In terms of a direct connection between THIQs and SERM-based breast cancer therapy, 
pharmaceutical companies were quick to pick up on this important association. In a series of studies, 
researchers from Novartis9,10 and Pfizer11 compared the well-known SERM used in the clinic, Lasofoxifene (3), 
to small libraries of THIQ-derived analogues, some examples (4) of which are shown in Figure 2.  
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Figure 2.  The clinical agent Lasofoxifene 3 and examples of THIQ analogues thereof.   
 
The researchers from these companies determined that the THIQ ring system of Lasofoxifene 3 could 
readily be mimicked by the THIQ system, and importantly, it was noted that many of the THIQ analogues 
displayed an improved antagonistic/agonistic estrogen modulation effect compared to Lasofoxifene 3.  
A recent series of papers by Redda and co-workers describes their investigations into the utilization of 
THIQ scaffolds as potential agents applicable in anti-breast cancer therapies.12-14 Redda’s compounds 
comprised essentially mono- or un-substituted THIQs incorporating a hydrazine linker joining substituted 
benzamides to the THIQ core. Figure 3 illustrates the structures of some of these molecules 5 and Redda 
reported that their IC50 values (in the μg/mL range) suggested that the compounds were more active against 
the human ER+ (MCF7) and ER− (MDA-MB-231) breast cancers when compared to the standard Tamoxifen 6, 
initially developed as a treatment for breast cancer.15 It should be noted that these researchers observed that 
their compounds acted via microtubule destabilization, i.e. they were independent of the ER.13 Other 
researchers, particularly Potter and co-workers, pioneered the concept of 2-substituted estratriene 





Figure 3.  Compounds 5, 7 and 8 compared to the clinical drug, Tamoxifen 6.  
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Further active THIQ-based compounds from the Redda group demonstrated that phenolic groups on the 
THIQ skeleton, such as compounds 7 and 8 in Figure 3, resulted in some of the most active compounds.13,14 
However, what caught our attention was the fact that so few of the THIQ compounds prepared by Redda and 
co-workers had the phenolic OH group in the 6-position, as was demonstrated to be rather important by 
Chesworth and colleagues.11 The importance of this phenolic group was also illustrated by our collaboration 
with the Brunsveld group, where it was demonstrated that the 6-OH group on compound 9 had a significant 
impact (up to 4 × lower EC50) on the ERα and ERβ EC50 activity of the compounds (Figure 4, a).
21,22 
The importance of the phenolic group was further supported by a recent publication from AstraZeneca in 
which it was disclosed that the phenol group was critical for the potency of molecules such as 10 in SERD 
antagonist activity.23 It should additionally be noted that in 2015 this company had the related THIQ-based 
AZD9486 11 in clinical trials as an oral estrogen receptor inhibitor.24,25 Mention should also be made here of 





Figure 4.  (a) THIQ-based fragment-like estrogen receptor ligands; (b) AstraZeneca and Novartis compounds.  
 
Further inspection of the molecules synthesized and tested by Redda12-15 indicated that firstly, most 
possess large aryl groups connected via hydrazine-themed linker groups to the nitrogen atom of the THIQ 
motif. Secondly, the aryl groups attached to the nitrogen atom were limited in terms of their number, type 
and position of functional groups on the aryl group (see earlier work regarding a series of tetrahydro-
isoquinoline-N-phenylamide derivatives by Lin and co-workers27). This latter factor led to our interest and thus 
to the preparation of small libraries of, amongst others, N-aryl THIQ analogues to provide a more in-depth 
investigation into the importance of these aryl groups and their linkers.  
Investigations by Redda,12-15 together with our own unpublished docking studies, indicated a measure of 
uncertainty as to how THIQ analogues containing an N-aryl linker group would behave within the binding 
pocket of the ER protein (it should also be noted that we were willing to expand this paradigm to include the 
question as to whether the motifs were in fact targeting tubulin, rather than the ER). To extend our 
investigation into this area, a further library of THIQ analogues containing differently substituted aryl groups 
on nitrogen were designed and synthesized in order to discover whether any activity could be significantly 
associated with this group. The strategy adopted was to thus solely focus on changes at the nitrogen atom, 
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while retaining the phenolic moiety of estradiol (2c in Figure 5) based on the tetrahydroisoquinolin-6-ol motif 





Figure 5.  Basic structure of THIQ-derived compounds synthesized for this project. 
 
 
Results and Discussion 
 
Based on our own interest in the synthesis and utilization of the THIQ skeleton,28-32 it was thus decided to 
synthesize some tetrahydroisoquinolin-6-ol-based libraries. To this end, 6-methoxy-1,2,3,4-tetrahydro-
isoquinoline was synthesized as the hydrobromide or hydrochloride salt 14 from commercially available 2-(3’-
methoxyphenyl)ethylamine 13 according to the reliable procedure of Zhong and co-workers (Scheme 1).33 
From this central core we envisaged generating 4 small 6-OH-THIQ libraries L1-4 illustrated in Scheme 1. It 
should be noted that initial investigations included working directly with the 1,2,3,4-tetrahydroisoquinolin-6-ol 
molecule 2b. However, significant selectivity issues encountered in terms of differentiating between amine 
and phenolic chemoselectivity, persuaded us to avoid any lengthy protection-deprotection strategies21 and to 
use the 6-methoxy THIQ scaffold throughout the protocols and demethylate the 6-MeO group at the last step 




Scheme 1. General approach to substituted THIQs. Reagents and conditions: (i) 37% CH2O, 1 N HCl, 60 
oC, 4 h; 
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THIQ set L1: Urea-linked THIQs 
Synthesis of the first small library of THIQ-derivatives involved treatment of the 6-methoxyTHIQ hydrobromide 
salt 14 with 1,1’-carbonyldiimidazole (CDI) to afford the urea analogue 15.34 However, direct treatment of 
compound 15 with the range of amines illustrated in Table 1, failed to displace the imidazole leaving group to 
provide the desired urea derivatives. In order to address this inactivity, methylation of the imidazole moiety of 
compound 15 with iodomethane in acetonitrile afforded the more active imidazolium iodide salt 16 in 
quantitative yield (Scheme 2).34 Three base-mediated protocols were tested for the urea-formation (Et3N, 
Cs2CO3 or n-BuLi), and in our hands treatment of the primary and secondary amines with n-BuLi, prior to 
addition of the THIQ salt 16, proved to be the best protocol for obtaining compounds 17 (Table 1), essentially 
supporting the findings by Grzyb et al.34 Apart from the substituted anilines utilized, and in order to expand 
the scope of the investigation, two substituted thiazoles (entries 1 and 2) were also chosen, as well as 
morpholine (entry 8) whose starting material, the corresponding 6-benzyloxy analogue of 16 was available 
from a different project in our laboratory. Piperazine (entry 9) was also used, but unfortunately, the piperazine 
derivative decomposed during its attempted synthesis. Finally, demethylation of compounds 17 into their 
corresponding free phenols 18 was achieved using either an excess of BBr3 in dichloromethane or AlI3 in 




Scheme 2. Synthesis of urea-linked THIQs. Reagents and conditions: (i) CDI, K2CO3, MeCN, rt , 12 h; (ii) MeI, 
MeCN, rt, 6 h; (iii) THIQ salt (1.1 equiv.), amine (2.0 equiv.): aEt3N (2.0 equiv.), MeCN at rt, 12 h or 
bCs2CO3 (2.0 
equiv.), MeCN at rt, 12 h or cn-BuLi (3.0 equiv.), THF at −78 oC–rt , 12 h; (iv) dBBr3 (3.0 equiv.), CH2Cl2 at 0 
oC, 24 
h or eAlI3 (5.0 equiv.), PhMe at 110 
oC, 24 h or fPd/C, H2, EtOH at 40 
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90b 17b -α 18b 
3 4-anisidine 
 
98c 17c 42d 18cα,β 
4 3-chloroaniline 
 
86c 17d 50e 18d 
5 3-fluoroaniline 
 
98c 17e 35e 18e 
6 4-chloroaniline 
 
44c 17f 50e 18f 
7 4-fluoroaniline 
 
81c 17g 3e 18g 
8 morpholine 
 





17i - 18i 
αUnstable molecule;     βonly HRMS was able to be determined ;    letters refer to the 
experimental conditions described in the legend of Scheme 2. 
 
THIQ Set L2: Thiourea-linked THIQs 
The second small library of compounds comprised a thiourea linker that was synthesized through application 
of 1,1’-thiocarbonyldiimidazole (TCDI),34 in an analogous manner to the first library of compounds. This second 
library was synthesized to establish whether the thiocarbonyl group could affect the bioactivity of the THIQ 
compounds. It might be envisaged that hydrogen bond interactions and/or the selectivity within the ER- or 
tubulin binding pocket could be differently impacted, due to the subtle differences in size and electronic 
nature of the thiocarbonyl group relative to the carbonyl group. 
THIQ–thiocarbamoyl imidazole 19 was therefore prepared by treatment of the hydrobromide salt 14 with 
TCDI (Scheme 3). Subsequent methylation of 19 as described before, afforded the salt 20 in essentially 
quantitative yield, but this time as a foam, which proved to be too hygroscopic for isolation. Compound 20 
was thus immediately treated with the amines listed in Table 2 as before, to afford thioureas 21, albeit in 
poorer and more inconsistent yields than in the case for the carbonyl compounds illustrated in Table 1 
(Scheme 3 and Table 2). As may also be noted in Table 2, yields in subsequent demethylations were not 
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acceptable and failed in one case (entry 2) after which alternative protocols needed to be sought to afford the 




Scheme 3. Synthesis of thiourea-linked THIQs. Reagents and conditions: (i) TCDI, K2CO3, MeCN, 5 
oC, 2 h, rt 18 
h; (ii) MeI, MeCN, rt, 12 h; (iii) THIQ salt (1.1 equiv.), amine (1.0 equiv.): Cs2CO3 (3.0 equiv.), MeCN at rt, 12 h; 
(iv) BBr3 (10.0 equiv.), CH2Cl2 at 0 
oC. 24 h. 
 
Table 2.  Results and conditions for the procedures followed in Scheme 3 
Entry Nucleophile Product 
Yield for 










80 21a 36 22a 
2 3-chloroaniline 
 
8α 21d - 22d 
3 morpholine 
 





21i - 22i 
α 35% of THIQ dimer was also isolated. 
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THIQ Set L2 – an alternative strategy 
In an effort to improve yields of the THIQ compounds incorporating the thiourea linker 21, reactions between 
6-methoxy-THIQ hydrobromide salt 14 and suitably substituted isothiocyanates were undertaken since this 
protocol 35 is perceived to be a reliable synthetic approach to thioureas.36,37 To this end, amines and anilines 
23 were treated with an excess of carbon disulfide under basic conditions, followed by desulfurylation, to 




Scheme 4.  Conversion of amines into isothiocyanates. Reaction conditions: (i) amine (1.2 equiv.), CS2 (5.0 
equiv.); (ii) Boc2O, DMAP or TsCl. For details see Table 3. 
 
Table 3.  Results and conditions for the syntheses of isothiocyanates 24 as depicted in Scheme 4 













2 23d  
 
NaH, THF  TsCl  48  34 
3 23e 
 
NaH, THF TsCl 48 85 
4 23f 
 
NaH, THF TsCl 48 77 
5 23g 
 
NaH, THF TsCl 48 36 
6 23j  
 
Et3N, EtOH  
Boc2O, 
DMAP  
1.5  68  
7 23k  
 
Et3N, EtOH  
Boc2O, 
DMAP  
1.5  77  
α Trace amounts isolated 
From a cursory look at Table 3 entry 1, it is clear that the relatively electron deficient 2-amino-5-
nitrothiazole 23b is unreactive towards carbon disulfide. Entries 6 and 7 illustrate a method described by 
Munch et al.38 in which the phenolic amines 23j and 23k were treated with a base in ethanol prior to 
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treatment with CS2. Apart from the use of Boc2O, desulfurylation could also be effected by the use of tosyl 
chloride,39 and in our hands the Boc2O method only worked well for entries 6 and 7, while the tosyl chloride 
method worked best for entries 2-5, albeit with variable yields. With isothiocyanates 24d-g, 24j and 24k in 
hand (not described in the experimental), they were treated with the THIQ hydrobromide salt 14 under basic 
conditions and readily afforded a new small library of thiourea products 21 in moderate yields illustrated in 
Scheme 5 and Table 4. It should be noted that 22j and 22k were produced directly from the 6-hydroxy-THIQ 
hydrobromide of 2b.40 Unfortunately, demethylation of the thiourea analogues 21d-g once again proved to be 
problematic when using the protocols applied previously, and unfortunately the demethylation of the 




Scheme 5.  Formation of the thiourea analogues. Reagents and conditions: (i) and (iii) Salt 14 (1.0 mmol), 
isocyanate 24 (1.2 mmol), MeCN and Et3N under reflux 12 h, (ii) Methods as described in Scheme 2. 
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R = Product 
Yield for 
step i or iii 
(%) 
# 
1 3-chlorophenyl Me 
 
(i) 40 21d 
2 3-fluorophenyl Me 
 
(i) 56 21e 
3 4-chlorophenyl Me 
 
(i) 79 21f 
4 4-fluorophenyl Me 
 
(i) 62 21g 
5 4-hydroxyphenyl  H  
 
(iii) 41  22j 
6 3-hydroxyphenyl  H  
 
(iii) 39  22k 
 
THIQ Set L3 – Sulfonamide-linked THIQs 
The third library L3 was comprised of coupled THIQ-aryl motifs joined by a sulfonamide functional group. In 
this instance, use of the 1,1'-sulfonylbis(1H-imidazolium) triflate salt 25 as described by Beaudoin et al.,41 
seemed to be a viable route. To this end, neutralization of THIQ hydrobromide 14 with a suitable base prior to 
addition of the sulfonyl imidazolium triflate salt 25 (Scheme 6) was essential for improving the homogeneity of 
the reaction, which in turn afforded a good yield of intermediate 26. Activation of the imidazole ring of 26, 
was again achieved by converting it into the corresponding imidazolium triflate salt 27 in quantitative yield 
upon treatment with methyl triflate at low temperature. This salt, 27, as with the other salts prepared earlier, 
proved to be hygroscopic and thus amines 23 (shown in Table 5) were directly added to the vacuum dried 27 
to afford the library of sulfonamides 28 listed in Table 5. Entry 1 in Table 5, illustrates that dimer 30 was the 
only product isolated from the reaction. Lowering the reaction temperature to 24 oC resulted in only starting 
material being recovered, which suggested that even 2-amino-4-methyl-thiazole was too weak a nucleophile 
to displace the imidazolium salt. However, stronger aniline nucleophiles (entries 2-7) afforded the desired 
products 28c-h in moderate to good yields at either 24 oC or 80 oC.  
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Scheme 6. Synthesis of sulfonamide-linked THIQs. Reagents and conditions: (i) K2CO3, CH2Cl2, 0 
oC–rt, 12 h; (ii) 
MeOTf, CH2Cl2, 0 
oC, 6 h; (iii) 27 (1.1 equiv.), amine (1.0 equiv.): a Et3N (2.0 equiv.), MeCN at 80 
oC, 12 h or b 
K2CO3 (2.0 equiv.), MeCN at rt, 12 h or 
c Cs2CO3 (3.0 equiv.), MeCN at 80 
oC, 12 h; (iv) d BBr3 (3.0 equiv.), CH2Cl2 
at 0 oC, 24 h or e AlI3 (5.0 equiv.), PhMe at 110 
oC, 24 h. 
Arkivoc 2019, iv, 245-279  Mabank, T. et al. 
 Page 257  ©ARKAT USA, Inc 
Table 5.  Reaction conditions for the formation of sulfonamides 29 as depicted in Scheme 6 













-a,α  -  
2 4-anisidine 
 
87b 28c 32e 29c 
3 3-chloroaniline 
 
83c 28d 34d 29d 
4 3-fluoroaniline 
 
46c 28e 10d 29e 
5 4-chloroaniline 
 
54c 28f 41d 29f 
6 4-fluoroaniline 
 
94c 28g 33d 29g 
7 morpholine 
 
70c 28h 25e 29h 
α Only dimer 30 was obtained;  letters refer to the experimental conditions described in the 
legend of Scheme 6. 
 
Demethylations were effected on all the molecules of this library using either BBr3 or AlI3 as indicated in 
Table 5, but again yields were generally on the low side, indicating that these systems are not easy to 
demethylate under the applied conditions. 
 
THIQ set L4: N-aryl THIQs 
The next small library of THIQ-derivatives, L4, was designed to have the nitrogen atom of the THIQ directly 
attached to an aromatic ring. Our first attempts involved direct treatment of lactone 32, synthesized from 3-
methoxyphenyl acetic acid 31 via an Oxy-Pictet-Spengler protocol,42 with various amines without solvent in a 
sealed tube containing AlCl3 at 150 
oC for 48 hours to produce a melt (Scheme 7).43 The latter process also 
facilitated ring closure to afford lactams 33a–g in variable yields ranging from 28–89% (Table 6). In terms of 
new structural features, the carbonyl at C3 was readily identified in the 13C NMR spectra by a signal at 
approximately δC 170.0 for all the lactam analogues. However, attempts to reduce the C3 carbonyl group of 33 
to afford 34 proved uncharacteristically challenging in our hands and only two of the lactams were successfully 
reduced by employing AlH2Cl to afford 34a (82%) and 34c (67%). Thus, to finalise this library, the lactams 33 
were demethylated under the All3 conditions to provide a range of 6-hydroxy-2-phenyl-1,4-dihydroisoquinolin-
3(2H)-ones 35, once again in rather inconsistent and variable yields (Table 6). A new approach towards the 
direct N-aryl-THIQs was therefore sought, as described in the next section. 
 
Arkivoc 2019, iv, 245-279  Mabank, T. et al. 
 Page 258  ©ARKAT USA, Inc 
 
 
Scheme 7.  Conversion of THIQ-based lactones into N-aryl lactams. Reagents and conditions: (i) CH2O, AcOH, 
rt, 5 days, 45–70%; (ii) lactone (1.0 mmol), amine (1.5 mmol) AlCl3 (0.2 mmol), sealed glass tube at 150 
oC for 
48 h; (iii) AlH2Cl, THF, reflux, 12 h; (iv) AlI3 (5.0 equiv.), PhMe, 110 
oC. 10 h. 
 
Table 6.  Reagents and conditions for the formation of lactams 33 and 35 as depicted in Scheme 7 
Entry Nucleophile Ar  
Yield for step 
ii (%) 






35 33a 45 35a 
2 4-anisidine 
 
40 33c 78 35c 
3 3-chloroaniline 
 
57 33d -α 35d 
4 3-fluoroaniline 
 
89 33e 89 35e 
5 4-chloroaniline 
 
37 33f -α 35f 
7 4-fluoroaniline 
 
29 33g 24 35g 
α No product obtained after work-up;  product contains N-p-hydroxyphenyl. 
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THIQ set 4: N-aryl THIQs – alternative approach to L4 
An alternative approach to the THIQ library L4, also employing the classical Pictet-Spengler protocol, was 
developed for generating the desired THIQ analogues having a direct N-aryl link 34 (Scheme 8). In this 
approach, treatment of 3-methoxyphenyl acetic acid 31 with a cooled solution (0 oC) of amines/anilines 23b 
and 23d–g in dichloromethane containing catalytic amounts of DMAP, as well as the coupling agent, N,N’-
dicyclohexylcarbodiimide (DCC)44 afforded amides 36 in good yields (Table 7). The very poor yield for 36b 
(16%, Table 7, entry 2) is undoubtedly due to both low solubility and poor nucleophilicity of amine 23b. 
Generally, the other amide couplings proceeded successfully, providing the products 36d–g for use in the next 
step. Reduction of the amides 36 was this time successfully accomplished by treatment with monochloroalane 
in tetrahydrofuran, followed by gentle heating at 80 oC. After work-up, amines 37d–g were obtained in 
reasonable yields and their structures were confirmed by all having a set of two 2-proton triplets between  
3.35–2.50 in their 1H NMR spectra and the clear absence of a C=O signal at  169.0–171.0 in their 13C NMR 
spectra. Failure of 36b to undergo reduction is ascribed to the presence of the nitro group which appears to be 
chemically incompatible under the reaction conditions. Subsequent Pictet-Spengler ring-closure was effected 
by treatment of the amines 37d–g with a mixture of paraformaldehyde in formic acid at 80 oC for 12 h,45 to 
afford THIQs 34e and 34g, structurally confirmed by an intense 2-proton methylene bridge singlet at  4.00–
4.50 in the 1H NMR spectra for the new products. Unfortunately, in our hands the chloroaryl-substituted 
compounds 34d and 34f were found to be relatively unstable and decomposed in solution within hours of 
formation. Satisfyingly, despite this challenge, the two crude products 34d and 34f were successfully 
demethylated using AlI3 in toluene to the corresponding desired phenols 38d and 38f in yields of 57 and 58% 
respectively. Finally, the two THIQ analogues 34e and 34g, as well as 34a and 34c (prepared earlier, Scheme 7), 
were demethylated with AlI3 in toluene at 110 
oC for the first two and BBr3 in dichloromethane for the latter 





Scheme 8. Synthesis of N-aryl THIQs. Reagents and conditions: (i) amines (23b, 23d–g), DCC, DMAP (cat.), 
CH2Cl2 , rt , 12 h; (ii) LiAlH4/AlCl3, THF, reflux 5 h; (iii) CH2O, formic acid, 80 
oC, 12 h; (iv) a BBr3 (3.0 equiv.), 
CH2Cl2, 0 
oC, 12 h or b AlI3 (5.0 equiv.), PhMe, 110 
oC, 10 h. 
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  34a (82)α 38a(45) 
2 
 
36b (16) - - - 
3 
 
36d (66) 37d (98) 34dβ 38d (57) 
4 
 
36e (94) 37e (73) 34e (75) - 
5 
 
36f (87) 37f (88) 34fβ 38f (58) 
6 
 
36g (56) 37g (96) 34g (98) 38g (55) 
7 
 
  34c(67)α 38j (38)  
α Obtained as shown in Scheme 7; β Compound proved difficult to purify and so utilized directly 
in next reaction;  Product unstable;  product contains N-p-hydroxyphenyl group. 
 
Preliminary biological evaluations 
In terms of a pre-screening of the compounds in hand, a selected set was sent to the Council for Scientific and 
Industrial Research (CSIR, Pretoria, South Africa) for cell proliferation inhibition assay using the MCF7 (invasive 
ductal carcinoma) cell line. The assay was performed by first printing or spotting the phenols 18d, 18f, 18g, 
18h, 29h, 35a, 35c, 35e, 35g, 38a, 38g, 38f and 38j, at the concentration of 2.5 mg/mL, on a 2.5 × 6.4 cm glass 
slide. The printing solution was prepared as described by Erfle and Pepperkok.46 The slide was then placed in a 
tissue culture plate followed by the addition of MCF7 cells at the concentration of 1.5 x 106 cells / 10 mL of 
tissue culture media. The plate was placed in an incubator at 37 °C and 5% CO2 for 4 days. Post cell culture, the 
cells were treated with immunofluorescent agents (sulforhodamine B, 568 nm; phalloidin, 488 nm and 4,6-
diamidino-2-phenylindole, dihydrochloride (DAPI), 408 nm). Imaging was performed using a three channel 
Cytation3 cell imaging Multi-Mode Reader. The changes in blue (DAPI staining of cells nuclei) and green 
(phalloidin staining of cells cytoskeleton) fluorescence intensity at the spot representing each compound were 
taken to be indicative of changes in MCF7 viability (apoptosis or inhibition of cell proliferation) and 
experiments were performed in duplicate. Persomics analysis software was utilized to process images and 
data quantification was performed using Microsoft Excel. The results for the THIQ-based compounds are 
depicted in Figure 6. 
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Figure 6: Percentage growth of MCF7 cells treated with selected compounds (2.50 mg/mL over 4 days). 
 
Unfortunately, the small set of compounds tested were underwhelming in their ability to inhibit the 
proliferation of the MCF7 cells. As can be seen from Figure 6, the synthesized compounds had little effect. It 
should be noted that a number of reference compounds were included in the anti-proliferation assay, some of 
which provided better growth inhibition. The results of this initial screening indicate that a much larger set of 
compounds will need to be evaluated to note whether further compounds with higher activity can be 





Four small libraries of THIQ analogues, in which the nitrogen atom was employed as a linker group, were 
synthesized to reflect the urea-, thiourea- and sulfonamide-linked functional groups, as well as their direct N-
Ar analogues. Initial observations revealed that the last step demethylation was problematic, frequently 
resulting in the final products in low yields only – the development of an alternative strategy making use of 
easier to remove phenol protecting groups is thus an ongoing concern in our laboratories. Initial evaluations of 
the compounds synthesized in an antiproliferative assay against the MCF7 carcinoma cell line revealed a lack 






General. Melting points were measured on a Gallenkamp melting point apparatus. Reaction times were 
determined using thin layer chromatography (TLC) on fluorescent silica gel plates HF254 (Merck) and viewed 
under UV radiation or employing reagents including potassium permanganate, ninhydrin, p-anisaldehyde, 
cerium ammonium molybdate, 2,4-dinitrophenylhydrazine and iodine vapors. Silica gel 60 (70-230 mesh) was 
used for gravity column chromatography and 230-400 mesh was used for flash chromatography. Silica 
sensitive compounds were purified using Aluminium oxide 90 active neutral 0.063-0.200 mm (70-230 
mesh)(Merck). Nuclear magnetic resonance (NMR) spectra were recorded on Varian Gemini-300 (1H NMR at 
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300 MHz and 13C at 75 MHz) and Varian VXR-400 (1H NMR at 400 MHz and 13C at 101 MHz) spectrometers. 
Chemical shifts (δ) and coupling constants (J) are represented in ppm and Hertz units respectively. Positive 
electron spray impact (ESI+) high resolution mass spectra (HRMS) were recorded on a Unicam Automass mass 
spectrometer in conjunction with a gas chromatogram. All reactions were performed under a dry nitrogen 
atmosphere. The following compounds sent for biochemical evaluation were evaluated for purity by way of 
LCMS (% purity in parenthesis): 18h (99%), 29h (93%), 35a (97%), 35c (98%), 35e (97%), 35g (99%), 38a (88%), 
38g (96%), 38f (96%) and 38j (92%). 
THIQ set L1: General approach to the synthesis of THIQ–carbamoyl imidazoles34 
(1H-Imidazol-1-yl)[6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl]methanone (15). To a cooled (0 oC) solution of 
1,1’-carbonyldiimidazole (350 mg, 2.20 mmol) in anhydrous MeCN (25 mL) was added THIQ 14 (326 mg, 2.00 
mmol) and K2CO3 (4.00 mmol). The resulting mixture was stirred at 24 
oC for 18 h and then concentrated 
under reduced pressure to afford a residue which was purified by column chromatography (100% EtOAc) to 
give imidazole 15 (493 mg, 96%) as a colourless oil, Rf  0.31 (100% EtOAc). This intermediate was immediately 
used without further purification in the next synthetic step. 1H NMR (300 MHz, CDCl3): δH 7.86 (d, J 0.9 Hz, 1H, 
imidazole-H), 7.20 (d, J 1.4 Hz, 1H, imidazole-H), 7.05 (d, J 1.4 Hz, 1H, imidazole-H), 6.95–6.92 (m, 1H, ArH), 
6.71–6.64 (m, 2H, ArH), 4.61 (s, 2H, ArCH2N), 3.78–3.67 (m, 5H, overlapping signals - NCH2 and OMe), 2.90 (t, J 
6.0 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.1 (ArCH2CH2), 44.7 (CH2CH2N), 48.3 (ArCH2N), 55.6 
(OMe), 113.3 (ArCH), 113.9 (ArCH), 118.2 (ArCH), 124.1 (ArC), 127.6 (ArCH), 130.1 (ArCH), 135.3 (ArC), 137.1 
(ArCH), 151.4 (C-O), 159.0 (C=O).  
1-(6-Methoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3’-methyl-1H-imidazol-3-ium iodide (16). To a 
suspension of carbamoyl imidazole 15 (748 mg,2.91 mmol) in anhydrous MeCN (24 mL) was added 
iodomethane (0.960 mL, 15.5 mmol) and the resulting mixture stirred for 6 h to afford a precipitate which was 
filtered off to give 16 (1160 mg, 100%) as an off white solid, mp 172–173 oC, Rf 0.00 (100% EtOAc).This 
intermediate was used without further purification for the next step in the synthesis. 1H NMR (300 MHz, 
DMSO-d6): δH 9.62 (s, 1H, imidazole-H), 8.10–8.09 (m, 1H, imidazole-H), 7.89–7.88 (m, 1H, ArH), 7.13 (brs, 1H, 
ArH), 6.84–6.81 (m, 2H, ArH), 4.67 (s, 2H, ArCH2N), 3.94 (s, 3H, imidazole-Me), 3.75–3.68 (m, 5H, overlapping 
signals - OMe and CH2), 2.95 (t, J 5.8 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, DMSO-d6, some quaternary carbons 
not observed): δC 55.3 (OMe), 112.9 (ArCH), 113.2 (ArCH), 121.1 (ArC), 123.8 (ArCH), 127.6 (ArCH), 135.7 (ArC), 
137.8 (ArCH), 147.3 (C-O), 158.3 (C=O). 
6-Methoxy-N-(4’-methylthiazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxamide (17a). To a mixture of 2-
amino-4-methylthiazole (120 mg, 1.08 mmol) and Et3N (0.150 mL, 1.08 mmol) in anhydrous MeCN (15 mL) 
stirred at 24 oC for 30 min was added the imidazolium salt 16 (216 mg, 0.542 mmol) and the reaction mixture 
stirred for 18 h. The reaction mixture was washed with aqueous 1 N HCl solution (50 mL × 2) followed by 
extraction with EtOAc (20 mL × 2). The residue, obtained by reduction of the solvent volume, was purified by 
column chromatography (50:50 EtOAc/Hexane) to afford the amide 17a (132 mg, 80%) as an orange oil, Rf 
0.39 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δH 6.95 (d, J 8.4 Hz, 1H, ArH), 6.75 (dd, J 8.4, 2.5 Hz, 1H, 
ArH), 6.66 (d, J 2.5 Hz, 1H, ArH), 6.39 (s, 1H, thiazole-ArH), 4.55 (s, 2H, ArCH2N), 3.78 (s, 3H, OMe), 3.70 (t, J 5.9 
Hz, 2H, CH2), 2.84 (t, J 5.9 Hz, 2H, ArCH2CH2), 2.27 (s, 3H, thiazole-Me). 
13C NMR (75 MHz, CDCl3, some 
quaternary carbons not observed): δC 16.8 (thiazole-Me), 29.1 (ArCH2CH2), 41.5 (CH2), 45.3 (ArCH2N), 55.4 
(OMe), 107.1 (ArCH), 112.8 (ArCH), 113.4 (ArCH), 124.8 (ArC), 127.5 (ArCH), 135.9 (ArCNH), 154.5 (C-O), 158.5 
(C=O). HRMS ESI+: calcd for C15H18N3O2S [M+H]
+ 304.1120, found 304.1111. 
6-Methoxy-N-(5’-nitrothiazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxamide (17b). To a suspension of 2-
amino-5-nitrothiazole (100 mg, 0.714 mmol), and Cs2CO3 (310 mg, 0.952 mmol) in anhydrous MeCN (20 mL), 
which was stirred at 24 oC for 30 min, was added the salt 16 (190 mg, 0.476 mmol) and stirring was continued 
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for 12 h. Work-up as before afforded a solid residue which was purified using column chromatography (30:70 
EtOAc/Hexane) to give 17b (143 mg, 90%) as a yellow powder, Rf 0.50 (30:70 EtOAc/Hexane). 
1H NMR (300 
MHz, DMSO-d6): δH 12.17 (s, 1H, NH), 8.58 (s, 1H, thiazole-H), 7.10 (d, J 8.4 Hz, 1H, ArH), 6.89–6.67 (m, 2H, 
ArH), 4.64 (s, 2H, ArCH2N), 3.89–3.62 (m, 5H, overlapping signals - OMe and CH2), 2.84 (t, J 5.9 Hz, 2H, 
ArCH2CH2). 
13C NMR (75 MHz, DMSO-d6): δC 28.3 (ArCH2CH2), 41.5 (CH2), 44.9 (ArCH2N), 55.1 (OMe), 112.5 
(ArCH), 113.2 (ArCH), 124.9 (ArCH), 127.2 (ArCH), 135.7 (ArC), 140.5 (ArCH), 142.1 (ArCNH), 153.8 (C-O), 157.9 
(C=O), 165.54 (ArCNO2). HRMS ESI
+: calcd for C14H15N4O4S [M+H]
+ 335.0814, found 335.0805. 
6-Methoxy-N-(4’-methoxyphenyl)-3,4-dihydroisoquinoline-2(1H)-carboxamide (17c). To a cooled (−78 oC) 
solution of anisole (80.0 mg, 0.649 mmol) in anhydrous THF (15 mL) was added n-BuLi (1.39 mL, 1.4 M, 1.94 
mmol) and the mixture was stirred for 1 h at −78 oC. The temperature was gradually allowed to increase to 24 
oC. Salt 16 (310 mg, 0.779 mmol) was then added and the reaction mixture was stirred at 24 oC for 12 h. Work-
up as described before, followed by chromatography (30:70 EtOAc/Hexane) afforded 17c as a brown oil (198 
mg, 98%), Rf 0.50 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.30–7.14 (m, 2H, ArH), 6.99 (d, J 8.4 
Hz, 1H, ArH), 6.84–6.60 (m, 4H, ArH), 6.32 (s, 1H, NH), 4.52 (s, 2H, ArCH2N), 3.73 (s, 3H, OMe), 3.74 (s, 3H, 
OMe), 3.63 (t, J 5.9 Hz, 2H, NCH2), 2.82 (t, J 5.9 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.7 
(ArCH2CH2), 41.7 (CH2), 45.6 (ArCH2N), 55.7 (2 × OMe), 112.9 (ArCH), 113.6 (ArCH), 114.4 (ArCH), 122.9 (ArCH), 
125.6 (ArCH), 127.7 (ArC), 132.4 (ArC), 136.6 (ArCNH), 155.8 (C-O), 156.2 (C-O), 158.69 (C=O). HRMS ESI+: calcd 
for C18H21N2O3 [M+H]
+ 313.3638, found 313.3632. 
N-(3’-Chlorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxamide (17d). In a similar way described 
for 17c above, 17d was obtained as a brown oil (178 mg, 86%) yield as a brown oil that waxified at low 
temperatures, Rf 0.50 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.47 (d, J 1.9 Hz, 1H, ArH), 7.31–
7.07 (m, 2H, ArH), 7.06–6.90 (m, 2H, ArH), 6.85–6.61 (m, 3H, ArH and NH), 4.55 (s, 2H, ArCH2N), 3.77 (s, 3H, 
OMe), 3.65 (t, J 6.0 Hz, 2H, CH2), 2.83 (t, J 6.0 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.3 (ArCH2CH2), 
41.6 (CH2), 45.4 (ArCH2N), 55.4 (OMe), 112.7 (ArCH), 113.4 (ArCH), 118.3 (ArCH), 120.3 (ArCH), 123.1 (ArCH), 
125.2 (ArCH), 127.4 (ArC), 129.8 (ArCH), 134.4 (ArC), 136.2 (ArCCl), 140.5 (ArCNH), 154.9 (C-O), 158.5 (C=O). 
HRMS ESI+ calcd for C17H18ClN2O2 [M+H]
+ 317.1057 (35Cl), found 317.1052. 
N-(3’-Fluorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxamide (17e). In a similar manner as 
described for 17c above, 17e was obtained as a brown oil (192 mg, 98%) that waxified at low temperature, Rf 
0.50 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δH 7.38–7.18 (m, 1H, ArH), 7.09–7.03 (m, 2H, ArH), 
6.85–6.70 (m, 4H, ArH), 6.45 (s, 1H, NH), 4.62 (s, 2H, ArCH2N), 3.83 (s, 3H, OMe), 3.70 (t, J 5.8 Hz, 2H, CH2), 
2.93 (t, J 5.8 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3, some quaternary carbons not observed): δC 29.3 
(ArCH2CH2), 41.5 (CH2), 45.3 (ArCH2N), 55.3 (OMe), 107.4 (ArCH), 109.5 (ArCH), 112.6 (ArCH), 113.3 (ArCH), 
114.9 (ArC), 127.3 (ArCH), 136.2 (ArCNH), 158.5 (C=O). HRMS ESI+ calcd for C17H18FN2O2 [M+H]
+ 301.1352, 
found 301.1356.  
N-(4’-Chlorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxamide (17f). In a similar manner as 
described for 17c above, 17f was obtained as a brown solid (91 mg, 44%), mp 105–107 oC, Rf 0.50 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δH 7.40–7.19 (m, 4H, ArH), 7.06 (d, J 8.4 Hz, 1H, ArH), 6.88–6.65 (m, 
2H, ArH), 6.45 (s, 1H, NH), 4.59 (s, 2H, ArCH2N), 3.80 (s, 3H, OMe), 3.76–3.65 (m, 2H, CH2), 2.90 (t, J 5.3 Hz, 2H, 
ArCH2CH2). 
13C NMR (75 MHz, CDCl3, some quaternary carbons not observed): δC 29.7 (ArCH2CH2), 41.8 (CH2), 
45.6 (ArCH2N), 55.7 (OMe), 113.0 (ArCH), 113.7 (ArCH), 121.5 (ArC), 125.1 (ArCH), 127.7 (ArCH), 129.2 (ArC), 
136.4 (ArCCl), 138.1 (ArCNH), 154.9 (ArCH), 155.2 (C-O), 158.4 (C=O). HRMS ESI+ calcd for C17H18ClN2O2 [M+H]
+ 
317.1057 (35Cl), found 317.1060. 
N-(4’-Fluorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxamide (17g). In a similar manner as 
described for 17c above, 17g was obtained as a brown solid (159 mg, 81%), mp 136–137 oC, Rf 0.50 (50:50 
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EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δH 7.38–7.28 (m, 2H, ArH), 7.10–6.91 (m, 3H, ArH), 6.83–6.68 (m, 
2H, ArH), 6.43 (s, 1H, NH), 4.59 (s, 2H, ArCH2N), 3.80 (s, 3H, OMe), 3.70 (t, J 5.9 Hz, 2H, CH2), 2.89 (t, J 5.9 Hz, 
2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.7 (ArCH2CH2), 41.8 (CH2), 45.6 (ArCH2N), 55.7 (OMe), 113.0 
(ArCH), 113.7 (ArCH), 115.8 (d, J 22.5 Hz, ArCH-F), 122.5 (d, J 7.7 Hz, ArCH-F), 125.5 (ArC), 127.7 (ArCH), 135.3 
(ArC), 136.6 (ArCNH), 155.5 (C-O), 157.6 (d, J 67.5 Hz, ArC-F), 158.8 (C=O). HRMS ESI+ calcd for C17H18FN2O2 
[M+H]+ 301.1352, found, 301.1348.  
6-[Benzyloxy-3,4-dihydroisoquinolin-2(1H)-yl(morpholino)]methanone (17h). In a similar manner as 
described for 17c above, 17h was obtained as a thick white oil (220 mg, 96%) from the corresponding 6-
benzyloxy imidazolium salt to 16 (donation from another project), Rf 0.48 (100% EtOAc). 
1H NMR (300 MHz, 
CDCl3): δH 7.39–7.15 (m, 5H, ArH), 6.93 (d, J 8.4 Hz, 1H, ArH), 6.80–6.62 (m, 2H, ArH), 4.96 (s, 2H, ArCH2O), 4.31 
(s, 2H, ArCH2N), 3.74–3.53 (m, 4H, morpholine – 2 x OCH2), 3.42 (t, J 5.8 Hz, 2H, CH2), 3.29–3.13 (m, 4H, 
morpholine – 2 × NCH2), 2.79 (t, J 5.8 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.0 (ArCH2CH2), 44.5 
(morpholine – 2 × NCH2), 47.4 (CH2), 48.4 (ArCH2N), 66.8 (morpholine – 2 × CH2O), 70.2 (BnCH2O), 113.5 (ArCH), 
114.7 (ArCH), 126.1 (ArC), 127.4 (ArCH), 128.0 (ArCH), 128.7 (ArCH), 135.9 (ArC), 137.1 (BnC), 157.5 (C-O), 
164.0 (C=O). HRMS ESI+ calcd for C21H24N2O3 [M+H]
+ 353.1865, found 353.1866. 
General procedure for demethylation using BBr3 (Method A)
47 
To a mixture of 1 M BBr3 in anhydrous CH2Cl2 (1.90 mL, 1.9 mmol) in a Schlenk tube cooled to −78 
oC, was 
slowly added the MeO-THIQ analogues (0.66 mmol) in anhydrous CH2Cl2 (0.50 mL). The reaction mixture was 
stirred for 2 h at −60 oC, followed by stirring for an additional 4 h at 24 oC. Ethanol was then slowly added until 
fuming ceased, after which the reaction mixture was poured into a saturated NaHCO3 solution (15 mL) and 
extracted with EtOAc (20 mL x 3). The solvent was dried and evaporated (rotary evaporator), to afford a 
residue which was purified by column chromatography (40:60 EtOAc/Hexane).  
General procedure for demethylation using All3 (Method B)
48 
To a cooled suspension of clean aluminium powder (180 mg, 6.66 mmol) in anhydrous toluene (20 mL) was 
added iodine (I2) (1.31 g, 10.3 mmol) and the mixture was stirred at 110 
oC, under nitrogen, until the red 
colour had disappeared. The reaction mixture was cooled to rt (~24 
oC) and then the MeO-THIQ analogues 
(0.69 mmol) were added, after which the reactions were stirred at 60 oC for 12 h. The reaction mixture was 
cooled to 24 oC and the excess AlI3 was quenched by the slow addition of water (20 mL). The reaction mixture 
was extracted with EtOAc (20 mL × 3), the organic solvent collected, dried and reduced (rotary evaporator) to 
afford a residue which was purified by column chromatography (40:60 EtOAc/Hexane).  
6-Hydroxy-N-(4’-methylthiazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxamide (18a) was obtained as a 
yellow solid from 17a, via Method A (123 mg, 64%), mp 199–200 oC, Rf 0.22 (50:50 EtOAc/Hexane). 
1H NMR 
(300 MHz, CDCl3): δH 6.36–6.33 (bs, 1H, ArH), 6.05–5.99 (m, 2H, ArH), 5.79 (bs, 1H, thiazole-H), 4.29 (brs, 2H, 
NH and OH), 3.98 (s, 2H, ArCH2N), 3.13–3.09 (m, 2H, NCH2), 2.19 (t, J 5.9 Hz, 2H, ArCH2CH2), 1.63 (d, J 1.1 Hz, 
3H, thiazole-Me). 13C NMR (75 MHz, DMSO-d6, no C=O signal was visible): δC 6.8 (thiazole-Me), 20.6 
(ArCH2CH2), 33.4 (CH2), 37.0 (ArCH2N), 70.1 (thiazole-CH), 97.5 (ArCH), 105.4 (ArCH), 106.4 (ArC), 115.9 (ArCH), 
118.9 (ArC), 127.8 (thiazole-ArC), 134.5 (ArCNH), 147.8 (C-O), 148.6 (C-O). HRMS ESI+ calcd for C14H16N3O2S 
[M+H]+ 290.0963, found 290.0955. 
6-Hydroxy-N-(4’-hydroxyphenyl)-3,4-dihydroisoquinoline-2(1H)-carboxamide (18c) was obtained as a thick 
white oil from 17c, via Method B (83 mg, 42%), Rf 0.14 (50:50 EtOAc/Hexane). The compound rapidly 
decomposed in solution as demonstrated by NMR spectroscopy. HRMS ESI+ calcd for C16H17N2O3 [M+H]
+ 
285.1239, found 285.1240.  
N-(3’-Chlorophenyl)-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxamide (18d) was obtained as a brown 
solid from 17d, via Method B (105 mg, 50%), mp 188–190 oC, Rf 0.50 (50:50 EtOAc/Hexane). 
1H NMR (300 
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MHz, CD3OD, OH and NH signals were not observed): δH 7.57–6.99 (m, 5H, ArH), 6.67–6.64 (m, 2H, ArH), 4.59 
(s, 2H, ArCH2N), 3.71 (t, J 5.9 Hz, 2H, NCH2), 2.86 (t, J 5.9 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CD3OD): δC 30.0 
(ArCH2CH2), 42.9 (CH2), 46.5 (ArCH2N), 114.8 (ArCH), 115.7 (ArCH), 119.9 (ArCH), 121.7 (ArC), 123.7 (ArCCl), 
125.4 (ArCH), 128.3 (ArCH), 130.7 (ArCH), 135.0 (ArC), 135.3 (ArCHCl), 137.3 (ArCNH), 157.1 (C-O), 157.4 (C=O). 
HRMS ESI+ calcd for C16H16ClN2O2 [M+H]
+ 303.0900 (35Cl), found 303.0910. 
N-(3’-Fluorophenyl)-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxamide (18e) was obtained as a white 
solid from 17e via Method B (69 mg, 35%), mp 166–168 oC, Rf 0.33 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, 
DMSO-d6): δH 9.25 (s, 1H, NH), 8.71 (brs, 1H, OH), 7.54–7.37 (m, 1H, ArH), 7.34–7.17 (m, 2H, ArH), 6.96 (d, J 8.2 
Hz, 1H, ArH), 6.80–6.53 (m, 3H, ArH), 4.51 (s, 2H, ArCH2N), 3.63 (t, J 5.9 Hz, 2H, NCH2), 2.75 (t, J 5.9 Hz, 2H, 
ArCH2CH2). 
13C NMR (75 MHz, DMSO-d6, no C-F coupling was observable): δC 28.7 (ArCH2CH2), 41.6 (CH2), 45.4 
(ArCH2N), 106.1 (ArCH), 106.5 (ArCH), 108.0 (ArCH), 108.3 (ArCH), 113.8 (ArCH), 115.0 (ArCH), 115.3 (ArCH), 
124.2 (ArC), [one extra signal 127.4 (ArCH)], 130.0 (ArC), 136.1 (ArCNH), 142.9 (ArC-F), 154.9 (C-O), 156.0 
(C=O). HRMS ESI+ calcd for C16H16FN2O2 [M+H]
+ 287.1196, found 287.1197. 
N-(4’-Chlorophenyl)-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxamide (18f) was obtained as a brown oil 
from 17f, via Method B (105 mg, 50%), Rf 0.50 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CD3OD, OH and NH 
signals not observed): δH 7.5–6.99 (m, 5H, ArH), 6.6–6.64 (m, 2H, ArH), 4.59 (s, 2H, ArCH2N), 3.72 (t, J 5.7 Hz, 
2H, NCH2), 2.86 (t, J 5.7 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CD3OD, some quaternary carbons not observed): 
δC 28.6 (ArCH2CH2), 41.4 (CH2), 45.0 (ArCH2N), 113.4 (ArCH), 114.3 (ArCH), 114.7 (ArC), 123.1 (ArCH), 123.6 
(ArCH), 124.1 (ArCH), 126.8 (ArCNH), 136.0 (ArCCl), 155.0 (C-O), 156.03 (C=O). HRMS ESI+ calcd for 
C16H16ClN2O2 [M+H]
+ 303.0793 (35Cl), found 303.0799. 
N-(4’-Fluorophenyl)-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxamide (18g) was obtained as a white 
solid from 17g, via Method B (6 mg, 3%), mp 225–226 oC, Rf 0.33 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, 
CD3OD, both OH and NH signals were not observed): δH 7.4–7.19 (m, 3H, ArH), 7.00 (d, J 7.9 Hz, 2H, ArH), 6.66 
(d, J 7.9 Hz, 2H, ArH), 4.58 (s, 2H, ArCH2N), 3.71 (t, J 5.7 Hz, 2H, CH2), 2.85 (t, J 5.7 Hz, 2H, ArCH2CH2). 
13C NMR 
(75 MHz, CD3OD, C-F coupling was not observed): δC 30.0 (ArCH2CH2), 42.9 (CH2), 46.5 (ArCH2N), 114.8 (ArCH), 
115.7 (ArCH), 123.5 (ArC), 125.4 (ArC), 128.3 (ArCH), 129.0 (ArCH), 129.5 (ArCH), 137.3 (ArCF), 139.9 (ArCNH), 
157.2 (C-O), 157.7 (C=O). HRMS ESI+ calcd for C16H16FN2O2 [M+H]
+ 275.1196, found 275.1204. 
[6-Hydroxy-3,4-dihydroisoquinolin-2(1H)-yl](morpholino)methanone (18h). To a stirred mixture of Pd (10% 
on activated charcoal) (81.0 mg, 0.075 mmol) in anhydrous MeOH (6.00 mL) containing a drop of acetic acid 
was added 17h (270 mg, 0.766 mmol) and then stirred under a hydrogen atmosphere (balloon) at 40 oC for 48 
h. The mixture was filtered through celite and concentrated under reduced pressure. The residue was 
partitioned between EtOAc (30 mL) and washed with saturated aqueous NaHCO3 (10 mL × 3). Solvent 
reduction (rotary evaporator) afforded a residue which was purified by column chromatography (100% EtOAc) 
to afford 18h (158 mg, 79%) yield as a white solid mp 188–190 oC, Rf 0.21 (50:50 EtOAc/Hexane). 
1H NMR (400 
MHz, DMSO-d6): δH 9.02 (brs, 1H, OH), 6.90 (d, J 8.1 Hz, 1H, ArH), 6.67 (dd, J 8.1, 2.1 Hz, 1H, ArH), 6.55–6.46 
(m, H, ArH), 3.58–3.48 (m, 4H, morpholine – 2 × OCH2), 3.28–3.21 (m, 6H, morpholine – 2 × NCH2 and NCH2), 
3.13 (dd, J 9.0, 3.8 Hz, 2H, CH2), 2.59 (dd, J 9.0, 3.8 Hz, 2H, ArCH2CH2). 
13C NMR (101 MHz, DMSO-d6): δC 18.6 
(ArCH2CH2), 34.6 (morpholine – 2 x NCH2), 41.5 (CH2), 44.4 (ArCH2N), 66.6 (morpholine – 2 × OCH2), 113.6 
(ArCH), 116.7 (ArCH), 126.4 (ArC), 131.4 (ArCH), 139.4 (ArC), 156.0 (C-O), 158.2 (C=O). HRMS ESI+ calcd for 
C14H19N2O3 [M+H]
+ 263.1317, found 263.1320. 
(1H-Imidazol-1-yl)[6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl]methanethione (19). A cooled (5 oC) solution 
of 1,1’-thiocarbonyldiimidazole (215 mg, 1.20 mmol) in anhydrous MeCN (100 mL) containing K2CO3 (138 mg, 
1.00 mm) was treated by the portion-wise addition of THIQ HBr 14 (244 mg,1.00 mmol), while maintaining the 
temperature of 5 oC for 2 h. The reaction mixture was allowed to warm to 24 oC and stirred for 18 h. The 
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reaction mixture was concentrated under reduced pressure to afford a residue which was purified with 
column chromatography (100% EtOAc). It is important to note that in order to prevent formation of the dimer, 
the portionwise addition of 14 was essential. In this way 19 (293 mg, 100%) was obtained a yellow oil, Rf 0.21 
(100% EtOAc). 1H NMR (300 MHz, CDCl3): δH 7.92–7.83 (m, 1H, imidazole-H), 7.26–7.19 (m, 1H, imidazole-H), 
7.08 (dd, J 1.4, 0.9 Hz, 1H, imidazole-H), 6.98 (s, 1H, ArH), 6.84–6.67 (m, 2H, ArH), 4.85 (s, 2H, ArCH2N), 4.00 (d, 
J 7.2 Hz, 2H, CH2), 3.78 (s, 3H, OMe), 3.01 (t, J 5.6 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3, some 
quaternary carbons not observed): δC 50.0 (ArCH2CH2), 53.3 (CH2), 55.4 (OMe), 113.1 (ArCH), 113.4 (ArCH), 
119.3 (imidazole-ArCH), 123.5 (ArC), 127.4 (ArCH), 129.9 (ArC), 137.2 (imidazole-ArCH), 159.0 (C-O), 178.2 
(C=S). HRMS ESI+ calcd for C14H15N3OS [M]
+ 273.0936, found 273.0940. 
6-Methoxy-[3,4 dihydroisoquinolin-2(1H)-yl]-3’-methyl-1H-imidazole-3-ium iodide (20). To a solution of 19 
(110 mg, 0.403 mmol) in anhydrous MeCN (24.0 mL) was added MeI (0.200 mL, 3.32 mmol) and the resulting 
mixture stirred at 24 oC for 12 h. The reaction mixture was concentrated under reduced pressure affording 20 
as a brown foam (184 mg, 100%) and used in the next step without further purification 
6-Methoxy-N-(4’-methylthiazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carbothioamide (21a). To a mixture of 2-
amino-4-methylthiazole (66.0 mg, 0.578 mmol) and Cs2CO3 (334 mg, 1.73 mmol) in anhydrous MeCN (15 mL), 
that had been stirring at 24 oC for 30 min, was added the salt 20 (184 mg, 0.403 mmol) and the reaction 
mixture was stirred at this temperature for 12 h. After the usual work-up the residue was purified with column 
chromatography (50:50 EtOAc/Hexane) and the desired product 21a was obtained as an orange oil (103 mg, 
80%), Rf 0.63 (40:60 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 12.42 (s, 1H, NH), 7.08 (d, J 7.3 Hz, 1H, ArH), 
6.86–6.67 (m, 2H, ArH), 6.30 (s, 1H, thiazole-H), 5.05 (s, 2H, ArCH2N), 4.18 (t, J 5.9 Hz, 2H, CH2), 3.72 (s, 3H, 
OMe), 2.83 (t, J 5.9 Hz, 2H, ArCH2CH2), 2.16 (s, 3H, thiazole-Me). 
13C NMR (75 MHz, CDCl3): δC 29.2 (thiazole-
Me), 46.7 (ArCH2CH2), 50.0 (CH2), 55.5 (ArCH2N), 55.6 (OMe), 112.7 (ArCH), 113.1 (ArCH), 114.1 (ArCH), 125.0 
(ArC), 127.6 (ArCH), 132.8 (ArCH), 136.4 (ArC), 157.7 (thiazole-ArCNH), 158.7 (C-O), 182.3 (C=S). HRMS ESI+ 
calcd for C15H18N3OS2 [M+H]
+ 320.0847, found 320.0887. 
N-(3’-Chlorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carbothioamide (21d). By an analogous 
protocol employed for 21a, 21d was obtained as a white solid (14.0 mg, 8%) from 20, mp 184–186 oC, Rf 0.20 
(10:90 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δH 7.30–7.21 (m, 3H, ArH), 7.19–7.00 (m, 3H, NH and ArH), 
6.86–6.68 (m, 2H, ArH), 4.86 (s, 2H, ArCH2N), 4.02 (t, J 5.7 Hz, 2H, ArCH2N), 3.80 (s, 3H, OMe), 2.96 (t, J 5.7 Hz, 
2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3, some quaternary carbons not observed): δC 29.3 (ArCH2CH2), 47.5 
(CH2), 50.7 (ArCH2N), 55.7 (OMe), 113.1 (ArCH), 113.4 (ArCH), 122.4 (ArC), 124.3 (ArCH), 125.8 (ArCH), 127.8 
(ArCH), 130.1 (ArCCl), 134.9 (ArCH), 136.4 (ArCH), 141.5 (ArCNH), 159.0 (C-O), 183.5 (C=S). HRMS ESI+ calcd for 
C17H18N2OSCl [M+H]
+ 333.0828 (35Cl), found, 333.0821. 
[6-Methoxy-3,4-dihydroisoquinolin-2(1H)-yl](morpholino)methanethione (21h). By an analogous protocol 
used for 21a above, 21h was obtained as a yellow oil (77 mg, 65%) from 20, Rf 0.25 (30:70 EtOAc/Hexane). 
1H 
NMR (300 MHz, CDCl3): δH 7.01 (d, J 8.4 Hz, 1H, ArH), 6.84–6.63 (m, 2H, ArH), 4.66 (s, 2H, ArCH2N), 3.91–3.82 
(m, 4H, morpholine-CH2N), 3.81–3.64 (m, 7H, overlapping signals- morpholine-OCH2 and OMe), 3.62–3.50 (m, 
2H, NCH2), 2.98 (t, J 5.8 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3, some quaternary carbons not observed): 
δC 28.6 (ArCH2CH2), 49.1 (CH2), 51.9 (morpholine-NCH2), 52.8 (ArCH2N), 55.1 (OMe), 66.3 (morpholine-CH2O), 
112.6 (ArCH), 113.2 (ArCH), 124.9 (ArCH), 127.0 (ArC), 135.6 (ArC), 158.3 (C-O), 193.69 (C=S). HRMS ESI+ calcd 
for C15H21N2O2S [M+H]
+ 293.1279, found, 293.1324. 
 
6-Hydroxy-N-(4’-methylthiazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carbothioamide (22a) was obtained on 
demethylation via Method A as an orange oil (74 mg, 36%) from 20, Rf 0.37 (40:60 EtOAc/Hexane). 
1H NMR 
(300 MHz, DMSO-d6): δH 6.19–6.15 (m, 1H, ArH), 5.83–5.79 (m, 2H, ArH), 5.60 (s, 1H, thiazole-H), 3.79 (s, 2H, 
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ArCH2N), 2.96–2.90 (m, 2H, NCH2), 2.02–1.98 (m, 2H, ArCH2CH2), 1.43 (s, 3H, thiazole-Me). 
13C NMR (75 MHz, 
DMSO-d6, some quaternary carbons not observed): δC 6.65 (thiazole-Me), 20.6 (ArCH2CH2), 33.5 (CH2), 37.0 
(ArCH2N), 97.4 (thiazole-CH), 101.6 (ArCH), 105.4 (ArCH), 106.4 (ArC), 115.9 (ArCH), 118.8 (ArC), 127.8 
(thiazole-CN), 147.6 (C-O), 158.4 (thiazole-C), 170.1 (C=S). HRMS ESI+ calcd for C14H16N3OS2 [M+H]
+, 306.0735, 
found, 306.0722. 
[6-Hydroxy-3,4-dihydroisoquinolin-2(1H)-yl](morpholino)methanethione (22h) was obtained via demethyl-
ation Method B as a brown oil (34.0 mg, 20%) from 20, Rf 0.32 (30:70 EtOAc/Hexane). 
1H NMR (300 MHz, 
CDCl3): δH 6.94 (d, J 8.2 Hz, 1H, ArH), 6.76–6.53 (m, 2H, ArH), 4.64 (s, 2H, ArCH2N), 3.90–3.71 (m, 4H, 
morpholine-2 × OCH2), 3.64–3.44 (m, 6H, morpholine-2 × NCH2 and NCH2), 2.94 (t, J 5.8 Hz, 2H, ArCH2CH2), 1.21 
(brs, 1H, OH). 13C NMR (75 MHz, CDCl3): δC 28.9 (ArCH2CH2), 49.5 (CH2), 52.3 (ArCH2N), 53.3 (morpholine-2 × 
CH2O), 66.8 (morpholine-2 × NCH2), 114.2 (ArCH), 115.3 (ArCH), 125.2 (ArC), 127.6 (ArCH), 136.2 (ArC), 155.0 
(C-O), 194.0 (C=S). HRMS ESI+ calcd for C14H19N2O2S [M+H]
+, 279.1167, found, 279.1166.  
6-Hydroxy-N-(4’-hydroxyphenyl)-3,4-dihydroisoquinoline-2(1H)-carbothioamide (22j). A mixture of 6-
hydroxy-THIQ hydrobromide 14 (191 mg, 0.782 mmol) and isothiocyanate 24j (142 mg, 0.939 mmol) 
containing Et3N (0.330 mL, 0.26 mmol) in anhydrous MeCN (10 mL) was stirred and heated under reflux for 12 
h. Saturated brine solution (5.0 mL) was added to the cooled solution which was extracted with EtOAc (20 mL 
x 2). The residue was purified using column chromatography (50:50 EtOAc/Hexane to afford 22j as a white 
solid (97 mg, 41%), mp 220–222 oC, Rf 0.43 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, DMSO-d6): δH 9.30 and 
9.32 (each s, each 1H, 2xOH), 9.04 (s, 1H, NH), 7.06–6.94 (m, 3H, ArH), 6.72–6.58 (m, 4H, ArH), 4.88 (s, 2H, 
ArCH2N), 3.98 (t, J 6.0 Hz, 2H, CH2), 2.85 (t, J 6.0 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, DMSO-d6,overlapping 
signals): δC 28.7 (ArCH2CH2), 46.1 (CH2), 49.6 (ArCH2N), 113.8 (ArCH), 114.8 (ArCH), 124.3 (ArCNH), 127.4 (ArC), 
128.2 (ArCH), 132.6 (ArCH), 136.6 (ArC), 155.0 (C-O), 156.3 (C-O), 181.3 (C=S). HRMS ESI+ calcd for C16H17N2O2S 
[M+H]+ 301.1011, found, 301.1017. 
6-Hydroxy-N-(3’-hydroxyphenyl)-3,4-dihydroisoquinoline-2(1H)-carbothioamide (22k). By a similar protocol 
to the above for 22j, 22k was obtained from 24k as a white solid (93 mg, 39%), mp 174–176 oC, Rf 0.68 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, DMSO-d6): δH 9.31 (bs, 2H, 2xOH), 8.32 (s, 1H, NH), 7.44–7.29 (m, 2H, ArH), 
7.16–7.02 (m, 3H, ArH), 6.66–6.61 (m, 2H, ArH), 4.68 (s, 2H, ArCH2N), 3.83 (t, J 6.0 Hz, 2H, CH2), 2.88 (t, J 6.0 
Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, DMSO-d6): δC 28.0 (ArCH2CH2), 43.1 (CH2), 46.6 (ArCN), 109.2 (ArCH), 
114.0 (ArCH), 115.1 (ArCH), 116.0 (ArCH), 120.7 (ArCH), 123.0 (ArCH), 124.3 (ArC), 127.6 (ArCH), 135.4 (ArC), 
143.4 (ArCNH), 148.7 (C-O), 156.2 (C-O), 182.1 (C=S). HRMS ESI+ calcd for C16H17N2O2S [M+H]
+ 301.1011, found, 
301.1023. 
N-(3’-Chlorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carbothioamide (21d). By a similar protocol to 
the above for 22j, 6-methoxyTHIQ hydrobromide 14 and isocyanate 24d afforded the desired 21d as a white 
solid (104 mg, 40%), mp 184–186 oC, Rf 0.20 (10:90 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.30–7.21 
(m, 3H, ArH), 7.19–7.00 (m, 3H, NH and ArH), 6.86–6.68 (m, 2H, ArH), 4.86 (s, 2H, ArCH2N), 4.02 (t, J 5.7 Hz, 2H, 
ArCH2N), 3.80 (s, 3H, OMe), 2.96 (t, J 5.7 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3, overlapping of signals): 
δC 29.3 (ArCH2CH2), 47.5 (CH2), 50.8 (ArCH2N), 55.7 (OMe), 113.1 (ArCH), 113.4 (ArCH), 122.4 (ArC), 124.3 
(ArCH), 125.8 (ArCH), 127.8 (ArCH), 130.1 (ArCCl), 134.9 (ArCH), 136.4 (ArCH), 141.5 (ArCNH), 159.0 (C-O), 
183.5 (C=S). HRMS ESI+ calcd for C17H18ClN2OS [M+H]
+, 333.0828 (35Cl), found, 333.0821. 
 
N-(3’-Fluorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carbothioamide (21e). By a similar protocol to 
the above for 22j, and employing isocyanate 24e, the desired thioanilide was obtained as a white solid (67 mg, 
56%), mp 184–186 oC, Rf 0.53 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.31–7.28 (m, 2H, ArH), 
7.14–6.75 (m, 6H, ArH and NH), 4.87 (s, 2H, ArCH2N), 4.03 (t, J 5.9 Hz, 2H, CH2), 3.82 (s, 3H, OMe), 2.98 (t, J 5.9 
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Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3, overlapping signals): δC 29.3 (ArCH2CH2), 47.5 (CH2), 50.9 
(ArCH2N), 55.7 (OMe), 111.3 (d, J 24.0 Hz, ArCH-F), 112.4 (d, J 17.3 Hz, ArCH-F), 113.2 (d, J 28.5 Hz, ArCH-F), 
119.3 (ArCH), 127.7 (ArC), 130.5 (ArCH), 136.4 (ArC), 157.3 (C-O), 182.8 (C=S). HRMS ESI+ calcd for C17H18FN2OS 
[M+H]+, 317.3949, found, 317.3942 . 
N-(4’-Chlorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carbothioamide (21f). By a similar protocol to 
the above for 22j and employing isocyanate 24f the desired 21f was obtained as a white solid (206 mg, 79%), 
mp 170–171 oC, Rf 0.33 (30:70 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.32–7.17 (m, 2H, ArH), 7.07–
7.04 (m, 4H, NH and ArH), 6.80–6.75 (m, 3H, ArH), 4.88 (s, 2H, ArCH2N), 4.02 (t, J 5.5 Hz, 2H, CH2), 3.81 (s, 3H, 
OMe), 2.96 (t, J 5.5 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.4 (ArCH2CH2), 47.3 (CH2), 50.6 (OMe), 
55.7 (ArCH2N), 113.0 (ArCH), 113.4 (ArCH), 124.7 (ArC), 126.1 (ArCH), 127.8 (ArCH), 129.4 (ArCH), 131.1 
(ArCCl), 137.95 (ArC), 138.8 (ArCNH), 159.1 (C-O), 182.7 (C=S). HRMS ESI+ calcd for C17H18ClN2OS [M+H]
+, 
333.0721 (35Cl), found 333.0825. 
N-(4’-Fluorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carbothioamide (21g). By a similar protocol to 
the above for 22j and employing isocyanate 24g the desired 21g was obtained as a white solid (74 mg, 62%), 
mp 156–158 oC, Rf 0.44 (30:70 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.27–7.20 (m, 2H, ArH and NH), 
7.08–7.01 (m, 4H, ArH), 6.81–6.75 (m, 2H, ArH), 4.89 (s, 2H, ArCH2N), 4.03 (t, J 5.9 Hz, 2H, CH2), 3.81 (s, 3H, 
OMe), 2.97 (t, J 5.9 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3, overlapping signals): δC 29.2 (ArCH2CH2), 46.8 
(CH2), 50.1 (OMe), 55.4 (ArCH2N), 112.9 (d, J 28.5 Hz, ArCH-F), 115.8 (d, J 22.5 Hz, ArCH-F), 124.7 (ArCH), 127.1 
(ArCH), 127.2 (ArC), 135.5 (ArCNH), 136.3 (ArCH), 158.9 (C-O), 182.5 (C=S). HRMS ESI+ calcd for C17H18FN2OS 
[M+H]+, 317.3949, found, 317.3942.  
2-[(1H-Imidazol-1-yl)sulfonyl]-6-methoxy-1,2,3,4-tetrahydroisoquinoline (26) 
To a cooled (0˚C) mixture of 25 41 (400 mg, 1.10 mmol) in anhydrous CH2Cl2 (50 mL) containing K2CO3 (276 mg, 
2.00 mmol) was added 6-MeO-THIQ.HBr 14 (244 mg, 1.00 mmol) with stirring which was continued for 12 h 
during which time the temperature was allowed to reach 24 oC. The reaction mixture was concentrated under 
reduced pressure and the residue was purified by a short column chromatography (50:50 EtOAc/Hexane). 
Sulfone 26 was obtained as a transparent oil (206 mg, 70%) and utilized directly in the next reactions without 
further purification, Rf 0.58 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δH 7.93 (d, J 3.0 Hz, 1H, imidazole-H), 
7.31 (d, J 3.0 Hz, 1H, imidazole-H), 7.15 (d, J 3.0 Hz, 1H, imidazole-H), 6.96 (d, J 8.5 Hz, 1H, ArH), 6.75 (dd, J 8.5, 
2.5 Hz, 1H, ArH), 6.61 (d, J 2.5 Hz, 1H, ArH), 4.35 (s, 2H, ArCH2N), 3.76 (s, 3H, OMe), 3.51 (t, J 6.0 Hz, 2H, CH2), 
2.88 (t, J 6.0 Hz, 2H, ArCH2CH2). HRMS ESI
+ calcd for C13H16N3O3S [M+H]
+, 294.0914, found, 294.0908 
1-[6-Methoxy-3,4-dihydroisoquinolin-2(1H)-yl]sulfonyl-3’-methyl-1H-imidazol-3-ium trifluoromethane sulf-
onate (27) 
To a cooled (0˚C) solution of 26 (735 mg, 2.50 mmol) in anhydrous CH2Cl2 (20 mL) was added methyl triflate 
(0.310 mL, 2.77 mmol) and stirring was continued for 4 h at 0 oC. The reaction mixture was concentrated 
under reduced pressure to afford 27 (1143 mg, 100%) as a beige semi-solid which was used without further 
purification. 1H NMR (300 MHz, DMSO-d6): δH 9.60 (m, 1H, imidazole-H), 8.04 (d, J 2.0 Hz, 1H, imidazole-H), 
7.76–7.67 (m, 1H, imidazole-H), 7.11 (d, J 8.5 Hz, 1H, ArH), 6.82 (dd, J 8.5, 2.6 Hz, 1H, ArH), 6.75 (d, J 2.6 Hz, 
1H, ArH), 4.64 (s, 2H, ArCH2N), 3.98 (s, 3H, OMe), 3.86–3.74 (m, 5H, overlapping signals-CH2 and NMe), 2.99 (t, 
J 6.2 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, DMSO-d6, overlapping signals): δC 29.0 (imidazole-Me), 37.4 
(ArCH2CH2), 46.4 (ArCH2N), 55.9 (OMe), 114.3 (ArCH), 114.6 (ArCH), 122.0 (ArC), 123.3 (ArCH), 126.5 (ArC), 
128.6 (imidazole-CH), 135.3 (imidazole-CH), 139.2 (imidazole-CH), 160.6 (C-O). 
General procedure for the coupling of 27 with heteroaryl amines.41 To a solution of the sulfamoyl 
imidazolium salt 27 (280 mg, 0.613 mmol) in anhydrous MeCN (25 mL) were added the various amine 
nucleophiles (c-h) (0.740 mmol) and the resultant mixture stirred under the conditions illustrated in Scheme 6. 
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After reactions were complete (tlc), solvent was removed and the residue purified by column chromatography 
(50:50 EtOAc/Hexane) to afford the following amino sulfones: 
6-Methoxy-N-(4’-methoxyphenyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (28c) was obtained as a brown 
oil (186 mg, 87%) by the general coupling procedure. Rf 0.41 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): 
δH 7.13 (dd, J 8.9, 0.9 Hz, 2H, ArH), 6.99–6.86 (m, 2H, ArH), 6.83–6.67 (m, 3H, ArH), 6.60 (s, 1H, NH), 4.39 (s, 
2H, ArCH2N), 3.86 (s, 3H, OMe), 3.65 (s, 3H, OMe), 3.49 (t, J 5.6 Hz, 2H, CH2), 2.76 (t, J 5.6 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.3 (ArCH2CH2), 44.2 (CH2), 47.3 (ArCH2N), 55.5 (2xOMe), 112.8 (ArCH), 113.6 
(ArCH), 114.6 (ArCH), 124.2 (ArCH), 124.6 (ArCH), 127.4 (ArC), 129.6 (ArCNH), 134.7 (ArC), 157.6 (C-O), 158.4 
(C-O). HRMS (ESI+) calcd for C17H21N2O4S [M+H]
+, 349.1177, found, 349.1207. 
N-(3’-Chlorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide (28d) was obtained as an orange 
oil (179 mg, 83%) by the general coupling procedure. Rf 0.22 (15:85 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): 
δH 7.37–6.86 (m, 4H, ArH), 6.84–6.48 (m, 3H, ArH), 4.43 (d, J 3.9 Hz, 2H, ArCH2N), 3.68 (brm, 5H, overlapping 
signals-OMe and CH2), 3.00–2.67 (m, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3, some quaternary carbons not 
observed): δC 29.0 (ArCH2CH2), 44.3 (CH2), 47.3 (ArCH2N), 55.4 (OMe), 113.0 (ArCH), 113.6 (ArCH), 118.0 
(ArCH), 120.0 (ArCH), 123.8 (ArCH), 124.7 (ArC), 127.4 (ArCH), 130.4 (ArC), 134.5 (ArCCl), 135.0 (ArCNH), 138.5 
(C-O). HRMS ESI+ calcd for C16H17ClN2O3S [M]
+, 351.0570 (35Cl), found, 351.0551. 
N-(3’-Fluorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide (28e) was obtained as a 
colourless oil (95 mg, 46%) by the general coupling procedure. Rf 0.37 (30:70 EtOAc/Hexane). 
1H NMR (300 
MHz, CDCl3): δH 7.20 (m, 2H, ArH), 6.99–6.67 (m, 5H, NH and ArH), 6.60 (d, J 2.3 Hz, 1H, ArH), 4.42 (s, 2H, 
ArCH2N), 3.80–3.51 (m, 5H, overlapping signals-OMe and CH2), 2.81 (t, J 5.9 Hz, 2H, ArCH2CH2). 
13C NMR (75 
MHz, CDCl3, no C-F coupling was observable): δC 29.0 (ArCH2CH2), 44.2 (CH2), 47.3 (ArCH2N), 55.4 (OMe), 107.0 
(ArCH), 107.4 (ArCH), 111.2 (ArCH), 111.4 (ArCH), 113.0 (ArCH), 113.6 (ArCH), 115.3 (ArCH), 123.8 (ArCH), 
127.4 (ArC), 130.6 (ArCH), 134.5 (ArC), 138.9 (ArCNH), 158.5 (C-O), 164.9 (ArCF). HRMS ESI+ calcd for 
C16H18FN2O3S [M+H]
+, 337.1022 (18F), found, 337.1024. 
N-(4’-Chlorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide (28f) was obtained as a 
translucent brown oil (118 mg, 54%) by the general coupling procedure. Rf 0.22 (15:85 EtOAc/Hexane). 
1H 
NMR (300 MHz, CDCl3): δH 7.22–7.19 (m, 3H, ArH), 7.10–7.06 (m, 2H, ArH), 6.94–6.91 (m, 1H, ArH), 6.73–6.70 
(m, 1H, ArH), 6.60 (brs, 1H, NH), 4.48 (s, 2H, ArCH2N), 3.84 (s, 3H, OMe), 3.61 (t, J 5.9 Hz, 2H, CH2), 2.86 (t, J 5.9 
Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.2 (ArCH2CH2), 44.4 (CH2), 47.5 (ArCH2N), 55.6 (OMe), 113.1 
(ArCH), 113.8 (ArCH), 121.9 (ArCH), 124.0 (ArC), 127.6 (ArCH), 129.6 (ArC), 130.3 (ArCH), 134.7 (ArCNH), 136.0 
(ArCCl), 158.7 (C-O). HRMS ESI+, calcd for C16H18ClN2O3S [M+H]
+, 353.0727 (35Cl), found, 353.0723. 
N-(4’-Fluorophenyl)-6-methoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide (28g) was obtained as a 
colourless oil (195 mg, 94%) by the general coupling procedure. Rf 0.37 (30:70 EtOAc/Hexane). 
1H NMR (300 
MHz, CDCl3): δH 7.01–6.95 (m, 2H, ArH), 6.78 – 6.77 (m, 3H, ArH), 6.74–6.63 (m, 1H, ArH), 6.61 (m, 1H, ArH), 
6.31 (brs, 1H, NH), 4.40 (s, 2H, ArCH2N), 3.77 (s, 3H, OMe), 3.51 (t, J 5.9 Hz, 2H, CH2), 2.78 (t, J 5.9 Hz, 2H, 
ArCH2CH2).
 13C NMR (75 MHz, CDCl3): δC 29.7 (ArCH2CH2), 44.5 (CH2), 47.6 (Ar CH2), 55.6 (OMe), 113.2 (ArCH), 
115.0 (ArCH), 117.3 (2xArCH), 125.7 (ArC), 128.9 (ArCH), 131.8 (2xArCH), 132.3 (ArC), 135.0 (ArC),156.4 (ArC-O) 
and 162.9 (ArC-F). HRMS ESI+ calcd for C16H18FN2O3S [M+H]
+, 337.1022, found, 337.1016. 
4-{[6-Methoxy-3,4-dihydroisoquinolin-2(1H)-yl]sulfonyl}morpholine (28h) was obtained as a white 
amorphous solid (134 mg, 70%) as per the general coupling procedure, mp 119–121 oC, Rf 0.44 (40:60 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δH 6.99 (d, J 8.4 Hz, 1H, ArH), 6.82–6.71 (m, 1H, ArH), 6.67 (sharp s, 
1H, ArH), 4.39 (s, 2H, ArCH2N), 3.85–3.64 (m, 7H, overlapping signals-OMe and morpholine-2xOCH2), 3.54 (t, J 
5.9 Hz, 2H, CH2), 3.28–3.15 (m, 4H, morpholine-2xNCH2), 2.91 (t, J 5.9 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, 
CDCl3): δC 29.3 (ArCH2CH2), 44.1 (morpholine-2xNCH2), 46.6 (CH2), 47.6 (ArCH2N), 55.4 (OMe), 66.5 
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(morpholine-2xOCH2), 113.0 (ArCH), 113.7 (ArCH), 124.4 (ArCH), 127.4 (ArC), 134.6 (ArC), 158.5 (C-O). HRMS 
ESI+ calcd for C14H21N2O4S [M+H]
+, 313.1222, found, 313.1218. 
6-Hydroxy-N-(4’-hydroxyphenyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (29c) was obtained via 
demethylation Method B from 28c, as a thick white oil (62 mg, 32%), Rf 0.24 (50:50 EtOAc/Hexane). 
1H NMR 
(300 MHz, CD3OD): δH 7.09–6.97 (m, 2H, ArH and NH), 6.85 (d, J 8.3 Hz, 1H, ArH), 6.77–6.54 (m, 3H, ArH), 6.50 
(d, J 6.5 Hz, 2H, ArH), 4.59 (brs, 1H, OH), 4.26 (s, 2H, ArCH2N), 3.38 (t, J 5.9 Hz, 2H, NCH2), 2.65 (t, J 5.9 Hz, 2H, 
ArCH2CH2). 
13C NMR (75 MHz, CD3OD): δC 20.7 (ArCH2CH2), 36.1 (NCH2), 39.1 (ArCH2N), 105.6 (ArCH), 106.7 
(ArCH), 107.3 (ArC), 115.2 (ArCH), 115.3 (ArCH), 116.2 (ArCH), 119.0 (ArCH), 121.3 (ArCH), 121.5 (ArC), 126.8 
(ArCNH), 146.8 (C-O), 147.7 (C-O). HRMS ESI+ calcd for C15H16N2O4S [M+H]
+, 321.0864, found, 321.0912. 
N-(3’-Chlorophenyl)-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide (29d) was obtained via demethyl-
ation Method A from 28c, as a colourless oil (77 mg, 34%), Rf 0.41 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, 
CDCl3): δH 7.28–7.24 (m, 1H, NH), 7.18 (d, J 8.0 Hz, 1H, ArH), 7.13–6.96 (m, 2H, ArH), 6.90 (d, J 8.3 Hz, 1H, ArH), 
6.71–6.51 (m, 2H, ArH), 4.71 (brs, 1H, OH), 4.41 (s, 2H, ArCH2N), 3.55 (t, J 6.0 Hz, 2H, NCH2), 2.77 (t, J 6.0 Hz, 
2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.0 (ArCH2CH2), 44.4 (CH2), 47.5 (ArCH2N), 114.3 (ArCH), 115.5 
(ArCH), 118.4 (ArCH), 120.4 (ArCH), 121.3 (ArC), 124.1 (ArCH), 125.0 (ArCH), 127.8 (ArCH), 130.6 (ArCCl), 135.0 
(ArC), 135.3 (ArCNH), 154.6 (C-O). HRMS ESI+ calcd for C15H16ClN2O3S [M+H]
+, 339.0571 (35Cl), found 339.0570. 
N-(3’-Fluorophenyl)-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide (29e) was obtained via 
demethylation Method A from 28e, as a brown oil (22 mg, 10%), Rf 0.32 (50:50 EtOAc/Hexane). 
1H NMR (300 
MHz, CDCl3): δH 7.38–7.08 (m, 2H, ArH and NH), 7.01–6.44 (m, 6H, ArH), 4.87 (s, 1H, OH), 4.41 (d, J 6.0 Hz, 2H, 
ArCH2N), 3.54 (t, J 6.0 Hz, 2H, NCH2), 2.77 (t, J 6.0 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.0 
(ArCH2CH2), 44.4 (CH2), 47.6 (ArCH2N), 107.6 (d, J 25.5 Hz, ArCH-F), 111.7 (d, J 30.75 Hz, ArCH-F), 114.3 (ArCH), 
115.5 (ArCH), 115.6 (ArCH), 115.6 (ArC), 124.1 (ArCH), 127.8 (ArCH), 130.8 (ArCH), 130.9 (ArC), 135.0 (ArCH), 
148.6 (ArCNH), 154.6 (C-O). HRMS ESI+ calcd for C15H16FN2O3S [M+H]
+, 323.0866, found, 323.0854.  
N-(4’-Chlorophenyl)-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide (29f) was obtained via demethyl-
ation Method A from 28f, as a colourless oil (94 mg, 41%), Rf 0.41 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, 
CDCl3): δH 7.27–7.21 (m, 3H, ArH and NH), 7.09–7.06 (m, 2H, ArH), 6.90–6.56 (m, 3H, ArH), 4.39 (s, 2H, 
ArCH2N), 3.71–3.35 (m, 2H, NCH2), 2.76 (m, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3, overlapping signals): δC 
29.0 (ArCH2CH2), 44.4 (CH2), 47.5 (ArCH2N), 114.3 (ArCH), 115.4 (ArCH), 122.2 (ArC), 127.8 (ArCH), 129.7 
(ArCH), 130.4 (ArC), 134.8 (ArCCl), 135.8 (ArCNH), 154.6 (C-O). HRMS ESI+ calcd for C15H16ClN2O3S [M+H]
+, 
339.0571 (35Cl), found 339.0556. 
N-(4’-Fluorophenyl)-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide (29g) was obtained via demethyl-
ation Method A from 28g, as a brown oil (71.0 mg, 33%), Rf 0.32 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, 
CDCl3): δH 7.12–7.06 (m, 2H, ArH), 7.96–6.83 (m, 6H, ArH and NH), 4.36 (d, J 10.3 Hz, 2H, ArCH2N), 3.51–3.47 
(m, 2H, NCH2), 2.71 (t, J 6.0 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.8 (ArCH2CH2), 44.0 (CH2), 47.3 
(ArCH2N), 112.9 (ArCH), 114.2 (ArCH), 116.0 (ArC), 116.3 (ArCH), 123.5 (d, J 8.2 Hz, ArCH-F), 125.7 (ArC), 126.6 
(ArCH), 133.5 (ArCNH), 151.3 (ArC-F), 161.8 (C-O). HRMS ESI+ calcd for C15H16FN2O3S [M+H]
+, 323.0866, found, 
323.0858. 
2-(Morpholinosulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (29h) was obtained via demethylation Method B 
from 28h as a white solid (45.0 mg, 25%), mp 168–170 oC, Rf 0.53 (100% EtOAc). 
1H NMR (300 MHz,CD3OD): δC 
6.94 (d, J 8.2 Hz, 1H, ArH), 6.72–6.51 (m, 2H, ArH), 4.37 (s, 2H, ArCH2N), 3.69 (sharp m, 4H, morpholine-
2xCH2O), 3.54 (t, J 5.5 Hz, 2H, NCH2), 3.22–3.18 (m, 4H, morpholine-2xNCH2), 2.86 (t, J 5.5 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CD3OD): δC 29.9 (ArCH2CH2), 45.3 (morpholine-2xNCH2), 47.7 (CH2), 48.6 (ArCH2N), 67.4 
(morpholine-2xCH2O), 114.9 (ArCH), 116.0 (ArCH), 124.6 (ArC), 128.3 (ArCH), 135.9 (ArC), 157.1 (C-O). HRMS 
ESI+ calcd for C13H19N2O4S [M+H]
+, 299.1066, found, 299.1055. 
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General procedure for the lactamization of lactone (32) 
A mixture of 6-methoxyisochroman-3-one 3242 (300 mg, 1.68 mmol), amine analogues (a – g) (2.52 mmol) and 
AlCl3 (45.0 mg, 0.340 mmol) were combined under anhydrous conditions in a sealed tube and heated at 150 
oC 
for 48 h. The reaction mixture was poured into aqueous 1 N HCl (5.0 mL) and extracted with EtOAc (20 mL x 2) 
to afford a brown residue which was purified with column chromatography (30:70 EtOAc/Hexane).  
6-Methoxy-2-(4’-methylthiazol-2-yl)-1,2-dihydroisoquinolin-3(4H)-one (33a) was obtained from 32 as a pale 
yellow residue (162 mg, 35%), Rf 0.76 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.27–7.25 (m, 1H, 
ArH), 6.84–6.75 (m, 2H, ArH), 6.58 (s, 1H, thiazole-H), 5.29 (s, 2H, ArCH2N), 3.83–3.80 (m, 5H, overlapping 
signals-OMe and CH2), 2.33 (s, 3H, thiazole-Me). 
13C NMR (75 MHz, CDCl3): δC 17.7 (thiazole-Me), 39.1 (ArCH2), 
49.7 (ArCH2N), 55.7 (OMe), 110.0 (thiazole-CH), 112.5 (ArCH), 113.3 (ArCH), 123.7(ArCH), 127.4 (ArC), 132.8 
(ArC), 147.0 (thiazole-CMe), 158.7 (thiazole-ArCN), 159.8 (C-O), 168.4 (C=O). HRMS ESI+ calcd for C14H15N2O2S 
[M+H]+, 275.0854, found, 275.0855. 
6-Methoxy-2-(4’-methoxyphenyl)-1,2-dihydroisoquinolin-3(4H)-one (33c) was obtained from 32 as a beige 
oily residue (191 mg, 40%), Rf 0.17 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.26–7.19 (m, 2H, 
ArH), 7.09–7.07 (m, 1H, ArH), 6.93–6.90 (m, 2H, ArH), 6.81–6.75 (m, 2H, ArH), 4.75 (s, 2H, ArCH2N), 3.81–3.73 
(m, 8H, overlapping signals-2xOMe and ArCH2). 
13C NMR (75 MHz, CDCl3): δC 39.2 (ArCH2), 54.3 (2xOMe), 55.8 
(ArCH2N), 112.6 (ArCH), 113.0 (ArCH), 114.5 (ArCH), 124.5 (ArCH), 126.5 (ArCH), 127.3 (ArCH), 134.3 (ArC), 
135.6 (ArC), 158.5 (ArCN), 159.6 (2xC-O), 169.5 (C=O). HRMS ESI+ calcd for C17H18NO3 [M+H]
+, 284.1287, found, 
284.1292. 
2-(3’-Chlorophenyl)-6-methoxy-1,2-dihydroisoquinolin-3(4H)-one (33d) was obtained from 32 as a white solid 
(277 mg, 57%), mp 87–88 oC, Rf 0.36 (40:60 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.37–7.10 (m, 5H, 
ArH), 6.82–6.78 (m, 2H, ArH), 4.80 (d, J 6.0 Hz, 2H, ArCH2N), 3.85–3.75 (m, 5H, overlapping signals-OMe and 
ArCH2). 
13C NMR (75 MHz, CDCl3, overlapping signals): δC 39.1 (ArCH2), 53.4 (OMe), 55.5 (ArCH2N), 112.4 
(ArCH), 112.7 (ArCH), 123.8 (ArCH), 125.8 (ArCH), 126.3 (ArCH), 126.8 (ArC), 130.0 (ArCCl), 132.7 (ArCH), 134.8 
(ArCN), 158.4 (C-O), 160.3 (C=O). HRMS ESI+ calcd for C16H15ClNO2 [M+H]
+, 288.0791 (35Cl), found, 288.0785. 
2-(3’-Fluorophenyl)-6-methoxy-1,2-dihydroisoquinolin-3(4H)-one (33e) was obtained from 32 as a white solid 
(407 mg, 89%), mp 108–110 oC, Rf 0.41 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.38–6.78 (m, 7H, 
ArH), 4.79 (s, 2H, ArCH2N), 4.01–3.55 (m, 5H, overlapping signals-ArCH2 and OMe). 
13C NMR (75 MHz, CDCl3, 
overlapping signals): δC 39.3 (ArCH2), 53.5 (OMe), 55.6 (ArCH2N), 112.7 (d, J 28.50 Hz, ArCH-F), 113.7 (d, J 21.00 
Hz, ArCH-F), 121.0 (ArCH), 123.9 (ArCH), 126.3 (ArCH), 130.2 (ArC), 133.7 (ArCH), 159.3 (C-O), 169.8 (ArCF), 
172.9 (C=O). HRMS ESI+ calcd for C16H15FNO2 [M+H]
+, 272.1087, found, 272.1075. 
2-(4’-Chlorophenyl)-6-methoxy-1,2-dihydroisoquinolin-3(4H)-one (33f) was obtained from 32 as a yellow 
solid (179 mg, 37%), mp 123–125 oC, Rf 0.38 (40:60 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.39–7.28 
(m, 4H, ArH), 7.12–7.09 (m, 1H, ArH), 6.82–6.78 (m, 2H, ArH), 4.76 (s, 2H, ArCH2N), 3.92–3.63 (m, 5H, 
overlapping signals-ArCH2 and OMe). 
13C NMR (75 MHz, CDCl3, overlapping signals): δC 39.2 (ArCH2), 53.6 
(ArCH2N), 55.6 (OMe), 112.5 (ArCH), 112.9 (ArCH), 124.0 (ArC), 126.4 (ArCH), 127.0 (ArCH), 129.4 (ArCH), 132.2 
(ArCH), 133.9 (ArCH), 140.7 (ArCCl), 157.2 (ArCN), 159.6 (C-O), 169.3 (C=O). HRMS ESI+ calcd for C16H15ClNO2 
[M+H]+, 288.0684 (35Cl), found, 288.0782. 
2-(4’-Fluorophenyl)-6-methoxy-1,2-dihydroisoquinolin-3(4H)-one (33g) was obtained from 32 as a brown oil 
(133 mg, 29%), Rf 0.38 (40:60 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.47–7.23 (m, 5H, ArH), 7.00–6.95 
(m, 2H, ArH), 4.93 (s, 2H, ArCH2N), 3.97 (m, 5H, overlapping signals-OMe and CH2). 
13C NMR (75 MHz, CDCl3): 
δC 39.2 (ArCH2CH2), 54.1 (ArCH2N), 55.8 (OMe), 112.8 (d, J 30.00 Hz, ArCH-F), 116.2 (ArC), 116.5 (ArCH), 124.3 
(ArC), 126.6 (ArCH), 127.7 (ArCH), 127.8 (ArCH), 134.1 (ArCN), 159.7 (ArCF), 162.9 (C-O), 169.5 (C=O). HRMS 
ESI+ calcd for C16H15FNO2 [M+H]
+, 272.1087, found, 272.1090. 
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6-Hydroxy-2-(4’-methylthiazol-2-yl)-1,2-dihydroisoquinolin-3(4H)-one (35a) was obtained from 33a via 
demethylation Method A as a yellow solid (78 mg, 45%), mp 204–206 oC, Rf 0.79 (5:95 MeOH/CH2Cl2). 
1H NMR 
(300 MHz, DMSO-d6): δH 9.58 (brs, 1H, OH), 7.25 (d, J 8.1 Hz, 1H, ArH), 6.86 (sharp m, 1H, thiazole-H), 6.69–
6.66 (m, 2H, ArH), 5.23 (s, 2H, ArCH2N), 3.83 (s, 2H, ArCH2), 2.32 (d, J 1.0 Hz, 3H, thiazole-Me). 
13C NMR (75 
MHz, DMSO-d6): δC 17.0 (thiazole-Me), 38.1 (ArCH2O), 48.7 (ArCH2N), 109.6 (thiazole-ArCH), 113.4 (ArCH), 
113.6 (ArCH), 121.7 (ArCH), 126.9 (ArC), 132.9 (ArC), 145.9 (thiazole-ArC), 156.9 (C-O), 158.4 (thiazole-ArCN), 
168.5 (C=O). HRMS ESI+ calcd for C13H13N2O2S [M+H]
+, 261.0653, found, 261.0701. 
6-Hydroxy-2-(4’-hydroxyphenyl)-1,2-dihydroisoquinolin-3(4H)-one (35c) was obtained from 33c via 
demethylation Method A as a beige solid (132 mg, 78%), decomposition temperature 230–240 oC, Rf 0.21 
(40:60 EtOAc/Hexane). 1H NMR (300 MHz, DMSO-d6): δH 9.45 (brs, 2H, 2xOH), 7.09–7.06 (m, 3H, ArH), 6.75 (d, 
J 8.6 Hz, 2H, ArH), 6.63 (d, J 8.6 Hz, 2H, ArH), 4.65 (s, 2H, ArCH2N), 3.57 (s, 2H, ArCH2). 
13C NMR (75 MHz, 
DMSO-d6, overlapping signals): δC 38.5 (ArCH2), 53.1 (ArCH2N), 113.3 (ArCH), 115.2 (ArCH), 123.3 (ArCH), 126.3 
(ArC), 126.8 (ArC), 134.2 (ArCN), 155.5 (C-O), 156.7 (C-O), 168.5 (C=O). HRMS ESI+ calcd for C15H14NO3 [M+H]
+, 
256.0929, found, 256.0935. 
2-(3’-Fluorophenyl)-6-hydroxy-1,2-dihydroisoquinolin-3(4H)-one (35e) was obtained from 33e via demethyl-
ation Method B as a white solid (159 mg, 89%), mp 118–200 oC, Rf 0.41 (50:50 EtOAc/Hexane). 
1H NMR (300 
MHz, CD3OD): δH 7.56–7.33 (m, 1H, ArH), 7.23–6.96 (m, 4H, ArH), 6.84–6.58 (m, 2H, ArH), 4.81 (s, 2H, ArCH2N), 
3.70 (s, 2H, ArCH2). 
13C NMR (75 MHz, CD3OD): δC 39.7 (ArCH2), 54.8 (ArCH2N), 114.4 (d, J 21.8 Hz, ArCH-F), 
114.7 (d, J 24.0 Hz, ArCH-F), 115.1 (ArCH), 122.8 (ArCH), 124.4 (ArCH), 127.7 (ArCH), 131.7 (ArCH), 134.8 (ArC), 
145.5 (ArC), 158.7 (C-O), 162.5 (ArCN), 165.9 (ArCF), 172.5 (C=O). HRMS ESI+ calcd for C15H13FNO2 [M+H]
+, 
258.0930, found, 258.0919. 
2-(4’-Fluorophenyl)-6-hydroxy-1,2-dihydroisoquinolin-3(4H)-one (35g) was obtained from 33g via demethyl-
ation Method B as a brown solid (43 mg, 24%), mp 115–117 oC, Rf 0.41 (50:50 EtOAc/Hexane). 
1H NMR (300 
MHz, DMSO-d6): δH 6.53 (m, 2H, ArH), 6.42–6.22 (m, 3H, ArH), 5.88 (d, J 6.1 Hz, 2H, ArH), 3.97 (d, J 3.2 Hz, 2H, 
ArCH2N), 3.77 (brs, 1H, OH), 2.88 (s, 2H, ArCH2). 
13C NMR (75 MHz, DMSO-d6, ArC and C=O signals not 
detected): δC 30.0 (ArCH2CO), 45.7 (ArCH2N), 105.4 (d, J 31.5 Hz, ArCH-F), 107.6 (d, J 23.0 Hz, ArCH-F), 118.1 
(ArCH), 119.8 (ArCH), 125.4 (ArCH). HRMS ESI+ calcd for C15H13FNO2 [M+H]
+, 258.0930, found, 258.0934.  
General procedure for the reduction of the acetamides 33.49,50 
To a suspension of AlH2Cl made by adding AlCl3 (140 mg, 1.06 mmol) to a stirred suspension of LiAlH4 (41.0 
mg, 1.08 mmol) in anhydrous THF (30 mL) at −3 oC in small portions followed by stirring at 24 oC for 30 min, 
was added the amides (0.713 mmol) in THF (4.0 mL). The reaction mixture was then stirred under reflux for 5 
h, cooled to 24 oC and carefully treated with water until no further effervescence occurred. The white solid 
(lithium aluminate) was separated by vacuum filtration and the filtrate extracted with EtOAc (20 mL × 2) to 
give the corresponding amines as pure oils. 
2-[6-Methoxy-3,4-dihydroisoquinolin-2(1H)-yl]-4’-methylthiazole (34a) was obtained from 33a as a thick 
yellow oil (153 mg, 82%), Rf 0.33 (20:80 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.09 (d, J 8.4 Hz, 1H, 
ArH), 6.83–6.65 (m, 2H, ArH), 6.12 (s, 1H, thiazole-rH), 4.58 (s, 2H, ArCH2N), 3.87–3.65 (m, 5H, overlapping 
signals-OMe and CH2), 2.95 (t, J 5.8 Hz, 2H, ArCH2CH2), 2.28 (d, J 1.1 Hz, 3H, thiazole-Me). 
13C NMR (75 MHz, 
CDCl3): δC 21.4 (thiazole-Me), 29.4 (ArCH2CH2), 46.1 (CH2), 49.6 (ArCH2N), 55.6 (OMe), 101.2 (ArCH), 112.9 
(ArCH), 113.6 (ArCH), 125.3 (ArC), 127.7 (ArC), 136.0 (ArC), 149.8 (ArC), 158.6 (C-O), 170.8 (ArCN). HRMS ESI+ 
calcd for C14H17N2OS [M+H]
+, 261.1062, found, 261.1070. 
6-Methoxy-2-(4’-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (34c) was obtained from 33a as an off-
white solid (129 mg, 67%), mp 116–118 oC, Rf 0.73 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.12–
7.11 (m, 1H, ArH), 6.93–6.90 (m, 2H, ArH), 6.78–6.69 (m, 3H, ArH), 6.58 (s, 1H, ArH), 4.38 (s, 2H, ArCH2N), 3.80 
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and 3.82 (each s, each 3H, 2xOMe), 3.47 (t, J 5.7 Hz, 2H, CH2), 2.75 (t, J 5.7 Hz, 2H, ArCH2CH2). 
13C NMR (75 
MHz, CDCl3): δC 29.4 (ArCH2CH2), 44.4 (CH2), 47.5 (ArCH2N), 55.6 (OMe), 55.7 (OMe), 113.0 (ArCH), 113.8 
(ArCH), 114.8 (ArCH), 124.4 (ArCH), 124.8 (ArCH), 127.6 (ArC), 129.8 (ArC), 134.9 (ArCN), 157.8 (C-O), 158.6 (C-
O). HRMS ESI+ calcd for C17H20NO2 [M+H]
+, 270.1494, found, 270.1494. 
General synthetic protocol for methoxyphenyl acetamides 36.44 
To a mixture of N,N‘-dicyclohexylcarbodimide (220 mg, 1.08 mmol), DMAP (11.1 mg, 9.03 × 10-5 mmol) and 3-
methoxyphenylacetic acid 31 (150 mg, 0.903 mmol) at 0 oC were added the respective amines (b–g) (0.903 
mmol) in anhydrous CH2Cl2 (5.0 mL) and the resultant reaction mixture was stirred at 24 
oC for 12 h. The 
suspension was filtered and the eluent concentrated under reduced pressure to yield a solid residue which 
was purified by flash chromatography (15:85 EtOAc/Hexane) to afford the products described below. The 
compounds were characterized by NMR spectroscopy (for some compounds HRMS too) and utilized directly in 
the next reduction step). 
2-(3-Methoxyphenyl)-N-(5’-nitrothiazol-2-yl)acetamide (36b) was obtained from 31 and 2-amino-5-nitro-
thiazole as an orange solid (42 mg, 16%), mp 119–120 oC, Rf 0.29 (30:70 EtOAc/Hexane). 
1H NMR (300 MHz, 
CDCl3): δH 9.52 (brs, 1H, NH), 8.22 (s, 1H, thiazole-H), 7.29–7.19 (m, 1H, ArH), 6.85–6.76 (m, 3H, ArH), 4.17–
3.55 (m, 5H, overlapping signals-OMe and CH2). 
13C NMR (75 MHz, CDCl3, overlapping signals): δC 43.4 (ArCH2), 
55.6 (OMe), 113.8 (thiazole-ArCH), 115.78 (ArCH), 121.8 (ArCH), 131.0 (ArCH), 133.4 (ArC), 140.4 (thiazole-
ArC), 160.7 (thiazole-ArCN), 161.2 (C-O), 169.5 (C=O). HRMS ESI+ calcd for C12H12N3O4S [M+H]
+, 294.0549, 
found, 294.0547.  
N-(3’-Chlorophenyl)-2-(3-methoxyphenyl)acetamide (36d) was obtained from 31 and 3-chloroaniline as a 
thick white oil (165 mg, 66%), Rf 0.66 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.51 (d, J 1.8 Hz, 
1H, ArH), 7.38–7.14 (m, 3H, ArH), 7.11–7.00 (m, 1H, ArH), 6.95–6.80 (m, 3H, ArH), 3.83 (s, 3H, OMe), 3.71 (s, 
2H, ArCH2). 
13C NMR (75 MHz, CDCl3): δC 45.1 (ArCH2), 55.4 (OMe), 113.4 (ArCH), 115.3 (ArCH), 117.9 (ArCH), 
120.0 (ArCH), 121.8 (ArCH), 124.6 (ArCH), 130.0 (ArCH), 130.5 (ArCH), 134.7 (ArCCl), 135.6 (ArCCH2), 138.9 
(ArCN), 160.2 (C-O), 169.0 (C=O). HRMS ESI+ calcd for C15H15ClNO2 [M+H]
+, 276.0791 (35Cl), found, 276.0780. 
N-(3’-Fluorophenyl)-2-(3-methoxyphenyl)acetamide (36e) was obtained from 31 and 3-fluoroaniline as a 
white solid (221 mg, 94%), mp 57–58 oC, Rf 0.46 (20:80 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3, NH signal 
was not detected): δH 7.45–7.11 (m, 3H, ArH), 7.06–6.69 (m, 5H, ArH), 3.80 (s, 3H, OMe), 3.69 (s, 2H, ArCH2). 
13C NMR (75 MHz, CDCl3, overlapping signals): δC 44.9 (ArCH2), 55.5 (OMe), 107.8 (d, J 26.25 Hz, ArCH-F), 111.4 
(d, J 21.00 Hz, ArCH-F), 113.3 (ArCH), 115.5 (d, J 12.75 Hz, ArCH-F)], 121.9 (ArCH), 130.3 (d, J 9.00 Hz, ArCH-F), 
136.0 (ArCN), 139.6 (d, J 10.50 Hz, ArCH-F), 161.6 (C-O), 164.8 (ArCF), 170.0 (C=O). HRMS ESI+ calcd for 
C15H15FNO2 [M+H]
+, 260.1087, found, 260.1083. 
N-(4’-Chlorophenyl)-2-(3-methoxyphenyl)acetamide (36f) was obtained from 31 and 4-chloroaniline a thick 
white oil (217 mg, 87%), Rf 0.41 (30:70 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3, NH signal was not observed): 
δH 7.51–7.50 (m, 5H, ArH), 7.11–6.80 (m, 3H, ArH), 3.83 (s, 3H, OMe), 3.71 (s, 2H, ArCH2). 
13C NMR (75 MHz, 
CDCl3): δC 45.1 (ArCH2), 55.4 (OMe), 113.4 (ArCH), 115.3 (ArCH), 117.8 (ArCH), 120.0 (ArCH), 121.8 (ArCH), 
124.6 (ArCH), 130.1 (ArCCl), 130.8 (ArCH), 130.4 (ArC), 135.7 (ArCNH), 158.5 (C-O), 168.2(C=O).  
N-(4’-Fluorophenyl)-2-(3-methoxyphenyl)acetamide (36g) was obtained from 31 and 4-fluoroaniline as a 
white solid (131 mg, 56%), mp 70–72 oC, Rf 0.46 (30:70 EtOAc/Hexane). 
1H NMR (300 MHz, CDCl3): δH 7.45–
7.11 (m, 3H, ArH), 7.06–6.69 (m, 5H, ArH), 3.80 (s, 3H, OMe), 3.69 (s, 2H, ArCH2). 
13C NMR (75 MHz, CDCl3): δC 
44.7 (ArCH2), 55.3 (OMe), 113.1 (ArCH), 115.2 (ArCH), 115.6 (d, J 22.5 Hz, ArCH-F), 121.8 (d, J 7.50 Hz, ArCH-F), 
130.3 (ArCH), 133.4 (ArCH), 135.8 (ArCN), 157.9 (ArCCH2), 160.20 (C-O), 161.1 (ArCF), 169.0 (C=O).  
Reduction of amides as described above for compounds 34a and 34c 
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3’-Chloro-N-(3-methoxyphenethyl)aniline (37d) was obtained from 36d as a thick yellow oil (184 mg, 98%), Rf 
0.82 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3, 7.28-7.15 (m, 2H, ArH), 6.98-6.60 (m, 5H, ArH), 3.80 (3H, 
s, OMe), 3.46 (t, J 6.9 Hz, 2H, ArCH2CH2NH), 2.81 (t, J 6.9 Hz, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 35.7 
(ArCH2), 45.0 (CH2), 55.5 (OMe), 111.6 (ArCH), 112.1 (ArCH), 112.8 (ArCH), 114.9 (ArCH), 117.6 (ArCH), 121.4 
(ArCH), 130.0 (ArCH), 130.6 (ArCH), 135.6 (ArCCl), 140.9 (ArCNH), 149.5 (ArC), 160.2 (C-O). HRMS ESI+ calcd for 
C15H17ClNO [M+H]
+, 262.0999 (35Cl), found, 262.0988.  
3’-Fluoro-N-(3-methoxyphenethyl)aniline (37e) was obtained from 36e as a white oil (128 mg, 73%), Rf 0.63 
(50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3, NH signal was obscured): δH 7.77–7.29 (m, 5H, ArH), 6.42–
6.28 (m, 3H, ArH), 3.80 (s, 3H, OMe), 3.38 (t, J 6.9 Hz, 2H, ArCH2CH2NH), 2.89 (t, J 6.9 Hz, 2H, ArCH2CH2NH). 
13C 
NMR (75 MHz, CDCl3): δC 35.3 (ArCH2CH2), 44.8 (CH2CH2NH), 55.2 (OMe), 99.6 (d, J 26.25 Hz, ArCH-F), 103.9 (d, 
J 9.00 Hz, ArCH-F), 108.8 (ArCH), 111.8 (ArCH), 114.6 (ArCH), 121.1 (ArCH), 120.0 (ArCH), 130.2 (ArCH), 130.4 
(ArC), 140.8 (ArCNH), 160.0 (C-O). HRMS ESI+ calcd for C15H17FNO [M+H]
+, 246.1294, found, 246.1290.  
4’-Chloro-N-(3-methoxyphenethyl)aniline (37f) was obtained from 36f as a thick yellow oil (164 mg, 88%), Rf 
0.80 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δH 7.30–7.18 (m, 1H, ArH), 7.17–7.08 (m, 2H,ArH), 
6.87–6.67 (m, 3H, ArH), 6.58–6.47 (m, 2H, ArH), 3.80 (s, 3H, OMe), 3.68 (brs, 1H, NH), 3.37 (t, J 6.8 Hz, 2H, 
ArCH2CH2), 2.88 (t, J 6.8 Hz, 2H, CH2CH2NH). 
13C NMR (75 MHz, CDCl3, overlapping signals): δC 35.6 (ArCH2CH2), 
45.3 (CH2CH2NH), 55.5 (OMe), 112.0 (ArCH), 114.3 (ArCH), 114.9 (ArCH), 121.4 (ArCH), 122.5 (ArCCl), 129.4 
(ArCH), 130.0 (ArC), 141.6 (ArCNH), 159.8 (C-O). HRMS ESI+ calcd for C15H17ClNO [M+H]
+, 262.0999 (35Cl), 
found, 262.0988. 
4’-Fluoro-N-(3-methoxyphenethyl)aniline (37g) was obtained from 36g as a translucent oil (168 mg, 96%), Rf 
0.71 (50:50 EtOAc/Hexane). 1H NMR (300 MHz, CDCl3, NH signal was obscured): δH 7.29–7.23 (s, 1H, ArH), 
6.78–6.03 (m, 5H, ArH), 6.58–6.54 (m, 2H, ArH), 3.90 (s, 3H, OMe), 3.38 (t, J 6.0 Hz, 2H, CH2CH2NH), 2.90 (t, J 
6.0 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 35.5 (ArCH2CH2), 45.6 (CH2CH2NH), 55.2 (OMe), 111.7 
(ArCH), 113.8 (d, J 7.50 Hz, ArCH-F), 114.6 (ArCH), 115.7 (d, J 21.75 Hz, ArCH-F), 121.1 (ArCH), 129.7 (ArCH), 
141.1 (ArC), 144.1 (ArCNH), 156.8 (ArCF), 159.9 (C-O). HRMS ESI+ calcd for C15H17FNO [M+H]
+, 246.1294, found, 
246.1292. 
General procedure for the Pictet-Spengler cyclization of amines 37.45 
A mixture of the amine substrates 37 (1.05 mmol) and paraformaldehyde (1.15 mmol) were heated in formic 
acid (5.0 mL) at 80 oC for 12 h. The reaction mixture was diluted with water (20 mL) and the pH adjusted to 5 
with NaHCO3 solution, followed by extraction with EtOAc (20 mL × 2). The residue was purified by chromato-
graphy in (20:80 EtOAc/Hexane).  
2-(3’-Fluorophenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (34e) was obtained from 37e as an orange oil 
(203 mg,75%), 1H NMR (300 MHz, CDCl3): δH 7.28–7.00 (m, 2H, ArH), 6.87–6.37 (m, 5H, ArH), 4.36 (s, 2H, 
ArCH2N), 3.80 (s, 3H, OMe), 3.55 (t, J 5.8 Hz, 2H, NHCH2), 2.96 (t, J 5.8 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, 
CDCl3, overlapping signals): δC 29.3 (ArCH2CH2), 45.8 (CH2), 49.6 (ArCH2N), 55.3 (OMe), 101.30 (d, J 25.5 Hz, 
ArCH-F), 104.4 (d, J 21.75 Hz, ArCH-F), 109.9 (ArCH), 112.4 (ArCH), 113.2 (ArCH), 126.2 (ArCH), 127.5 (ArCH), 
130.1 (ArC), 136.0 (ArCN), 157.2 (C-O), 159.3 (ArCF). HRMS ESI+ calcd for C16H17FNO [M+H]
+, 258.1294 (18F), 
found, 258.1288. 
2-(4’-Fluorophenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (34g) was obtained from 37g as a brown solid 
(266 mg, 98%), mp 75–78 oC, 1H NMR (300 MHz, CDCl3): δH 7.12–6.87 (m, 5H, ArH), 6.82–6.66 (m, 2H, ArH), 
4.28 (s, 2H, ArCH2N), 3.81 (s, 3H, OMe), 3.48 (t, J 5.8 Hz, 2H, NCH2), 2.97 (t, J 5.8 Hz, 2H, ArCH2CH2). 
13C NMR 
(75 MHz, CDCl3): δC 29.6 (ArCH2CH2), 48.1 (CH2), 51.7 (ArCH2N), 55.6 (OMe), 112.7 (ArCH), 113.6 (ArCH), 115.9 
(d, J 22.50 Hz, ArCH-F), 117.5 (d, J 7.50 Hz, ArCH-F), 126.8 (ArCH), 127.8 (ArC), 136.0 (ArC), 147.5 (ArCN), 155.2 
(ArCF), 158.4 (C-O). HRMS ESI+ calcd. C16H17NOF [M+H]
+, 258.1249 (18F), found, 258.1292. 
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2-(4’-Methylthiazol-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-ol (38a) was obtained from 34a by demethylation 
Method A as a yellow solid (73 mg, 45%), mp 120–122 oC, Rf 0.24 (40:60 EtOAc/Hexane). 
1H NMR (300 MHz, 
DMSO-d6): δH 6.34 (d, J 8.2 Hz, 1H, ArH), 6.10–5.94 (m, 2H, ArH), 5.78 (sharp m, 1H, thiazole-H), 4.29 (brs, 1H, 
OH), 3.97 (s, 2H, ArCH2N), 3.10 (t, J 6.0 Hz, 2H, CH2), 2.18 (t, J 6.0 Hz, 2H, ArCH2CH2), 1.63 (d, J 1.1 Hz, 3H, 
thiazole-Me). 13C NMR (75 MHz, DMSO-d6): δC 20.2 (thiazole-Me), 33.1 (ArCH2CH2), 36.7 (CH2), 69.8 (ArCH2N), 
97.2 (thiazole-CH), 105.1 (ArCH), 106.1 (ArCH), 115.6 (ArCH), 118.6 (ArC), 127.5 (ArC), 134.2 (thiazole-ArC), 
147.5 (C-O), 148.2 (thiazole-ArCN). HRMS ESI+ calcd for C13H15N2OS [M+H]
+, 247.0860, found, 247.0910. 
2-(4’-Hydroxyphenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (38j) was obtained from 34c via demethylation 
Method A as a yellow solid (61 mg, 38%), mp 178–180 oC 1H NMR (300 MHz, CD3OD): δH 7.05–6.89 (m, 3H, 
ArH), 6.83–6.69 (m, 2H, ArH), 6.67–6.53 (m, 2H, ArH), 4.12 (s, 2H, ArCH2N), 2.92 (t, J 5.8 Hz, 2H, ArCH2CH2). 
13C 
NMR (75 MHz, CD3OD, some quaternary carbons not observed): δC 30.0 (ArCH2CH2), 51.1 (CH2), 54.6 (ArCH2N), 
114.5 (ArCH), 115.7 (ArCH), 116.7 (ArC), 120.7 (ArCH), 126.1 (ArC), 126.8 (ArCH), 135.8 (ArCH), 136.7 (ArCH). 
HRMS ESI+ calcd for C15H16NO2 [M+H]
+, 242.1181, found, 242.1185. 
2-(3’-Chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (38d) was obtained via Method B from the transiently 
prepared 34d (not isolated) as white crystals (103 mg, 57%), mp 128–130 oC, Rf 0.36 (40:60 EtOAc/Hexane). 
1H 
NMR (300 MHz, CDCl3): δH 7.27–7.06 (m, 1H, ArH), 6.99 (d, J 8.0 Hz, 1H, ArH), 6.87 (d, J 1.9 Hz, 1H, ArH), 6.82–
6.51 (m, 4H, ArH), 4.30 (s, 2H, ArCH2N), 3.49 (t, J 5.3 Hz, 2H, CH2), 2.87 (t, J 5.3 Hz, 2H, ArCH2CH2). 
13C NMR (75 
MHz, CDCl3): δC 29.4 (ArCH2CH2), 46.3 (CH2), 50.0 (ArCH2N), 113.0 (ArCH), 114.1 (ArCH), 114.8 (ArCH), 115.2 
(ArCH), 118.4 (ArCH), 126.3 (ArCH), 128.0 (ArC), 130.5 (ArCH), 135.4 (ArC), 136.6 (ArCCl), 151.8 (ArCN), 154.8 
(C-O). HRMS ESI+ calcd for C15H15ClNO [M+H]
+, 260.0842 (35Cl), found, 260.0833. 
2−(4’−Chlorophenyl)−1,2,3,4−tetrahydroisoquinolin−6−ol (38f) was obtained via Method B from the 
transiently prepared 34f (not isolated) as a brown solid (104 mg, 58%), mp 116–117 oC; Rf 0.41 (50:50 
EtOAc/Hexane). 1H NMR (300 MHz, CDCl3): δH 7.27–7.15 (m, 2H, ArH), 7.00 (d, J 8.2 Hz, 1H, ArH), 6.90–6.81 (m, 
2H, ArH), 6.71–6.58 (m, 2H, ArH), 4.28 (s, 2H, ArCH2N), 3.48 (t, J 5.9 Hz, 2H, CH2), 2.89 (t, J 5.9 Hz, 2H, 
ArCH2CH2). 
13C NMR (75 MHz, CDCl3): δC 29.1 (ArCH2CH2), 46.6 (CH2), 50.3 (ArCH2N), 113.7 (ArCH), 115.0 
(ArCH), 116.4 (ArCH), 123.2 (ArCH), 124.0 (ArCH), 126.5 (ArC), 127.8 (ArCCl), 129.1 (ArCH), 136.3 (ArCH), 149.1 
(ArC), 149.6 (ArCN), 154.8 (ArCOH). HRMS ESI+: calcd for C15H15ClNO [M+H]
+, 260.0842, found, 260.0839. 
2-(4-Fluorophenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (38g) was obtained from 34g via demethylation 
Method B as an orange solid (93 mg, 55%), mp 105–107 oC, Rf 0.53 (50:50 EtOAc/Hexane). 
1H NMR (300 MHz, 
CDCl3): δH 7.06–6.88 (m, 5H, ArH), 6.74–6.59 (m, 2H, ArH), 4.26 (s, 2H, ArCH2N), 3.46 (t, J 5.7 Hz, 2H, NCH2), 
2.92 (t, J 5.7 Hz, 2H, ArCH2CH2). 
13C NMR (75 MHz, CDCl3, no C-F coupling detected): δC 29.4 (ArCH2CH2), 48.2 
(CH2), 51.9 (ArCH2N), 113.9 (ArCH), 115.3 (ArCH), 115.8 (ArCH), 116.1 (ArCH), 117.7 (ArCH), 126.1 (ArCH), 126.8 
(ArCH), 128.0 (ArC), 136.4 (ArC), 154.4 (ArCN), 157.8 (ArCOH), 159.9 (ArCF). HRMS ESI+ calcd for C15H15NOF 
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Supplementary Material 
 
A selection of 1H, 13C and HRMS spectra are available as representative examples of the final substituted 
tetrahydroisoquinolin-6-ols (18, 22, 29 and 38) and 6-hydroxy-2-aryl-1,2-dihydroisoquinolin-3(4H)-ones (35) 
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